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PART ONE

INTRODUCTION AND REVIEW OF THE LITERATURE

A.

PURPOSE

In several recent biochemical theories of alcoholic dependence, .
the possibility that biogenic amines may play a role in the expression of withdrawal symptoms has been discussed (1,2).

It has been

suggested that acetaldehyde (AcD) formed from the metabolism of ·
etqanol or catecholamine (CA)- derived aldehydes elevated due to AcD,
·.

condense with CAs in nerve terminals and chromaffin cells to produce
active 1,2,3,4, - tetrahydroisoquinoline (TIQ) alkaloid agents.
To date there are no .reports on the biosynthesis of TIQs in animal tissues during ethanol ingestion.

The purpose of this research

is to explore, with electron capture gas chromatography (EC/GC), the
possibility of TIQ alkaloid formation in rat brain and in adrenal
glands during acute or chronic intoxication with ethanol.

The quan-

titative changes in CA levels during alcohol metabolism are also
evaluated, using the highly sensitive chromatographic method.
B.

BACKGROUND

There appears to be little doubt that alcohol markedly affects
the function of the central nervous system (CNS), as reflected by
euphoria, loss of motor control, unconsciousness and severe
physiological dependence.

Unfortunately, there is no one satisfac-

tory explanation of the biochemical mechanisms by which ethanol
induces its neurological effects.

However, several lines of evidence

connecting the biogenic amines with the depressive and addictive

.

\

actions o.f this drug· have been put forth and are discussed in the
following three sections.
I. EFFECT OF ETHANOL AND ACETALDEHYDE ON NEUROAMINE METABOLISM

Ample evidence indicates that the biogenic amines (serotonin or
5-hydroxy-tryptamine (5-l:IT), norepinephrine (NE) and dopamine (DA)
are localized in specific neurons and nerve terminals in the CNS
(3,4) and that they function as chemical transmitters (5).

Inter-

action of these neuroregulatory compounds with the ethanol metabolite,
·.

AcD, might result in abnormal levels or types of amine metabolites
which would underlie the behavioral
ical alcoholism (6).

~berrations

manifested in

clin-

This relationship in fact has been the basis

for the numerous studies seeking to elucidate biochemical changes
involved in human alcoholism.
Reports of the changes in the pattern of urinary CA metabolites
after the ingestion of ethanol at various dose levels have appeared ·
frequently.

Smith et al (7) were the first to show that ethanol

altered the metabolism of infused NE in humans from the oxidative
pathway (vanillyl mandelic acid or VMA formation) to the reductive
pathway (3-methoxy-4-hydroxy phenylglycol or MHPG formation, Fig.1).
Similar findings have been reported by Davis and co-workers (8) in
that ethanol induced a shift from VMA to the glycol derivative after
intravenous (i.v.) ethanol injection in humans.

The alteration

in urinary _5- HT metabolites after ingestion of ethanol has been
reported to be similar
The

effect

of

ethanol

to

that
on

in

NE

metabolism

the peripheral

-2-

(9).

metabolism of DA in

OH

OH

HO

CH 0
3

COMT

HO

HO

lMAO
OH

OH
CH

3

CH 3 o

o
E1

HO

/s2

VMA

:

OH
CH 3 0

HO
MHPG

Fig. 1

Major pathway of norepinephrine catabolism in humans
El, aldehyde dehydrogenase
; E?, aldehyde reductase.
Modified from A.A. Smith and S. Gltlow (7)

-3-

humans has not been studied.

The results obtained in the ethanol-

intoxicated rat (10) show a decreased level of acid metabolites of
DA in urine, with no concomitant increase in the alcohol derivatives
(3-methoxy-4-hydroxyphenyl ethanol and 3,4-dihydroxyphenyl ethanol).
Apparently, however, the shift to a reductive pathway does not
occur in the CNS.

Tytell and Myers (11) compared the effect of

acute and chronic ethanol administration on 14c-5-Hr metabolism in
the rat brain.
'•

They did not observe large differences in CNS

production of 5-hydroxy-tryptophol between the alcoholic groups
and control.

Instead, compared to control rats, they found a signif-

icant CNS conversion of 14c-5-Hr to 5-hydroxyindole acetic acid
(5-HIAA) in both acute and chronic ethanol treated rats, with a
higher 5-HIAA level in acute ethanol treated rats.

A similar

observation of increase in 5-HIAA level in mouse brain, both after
acute and chronic administration of ethanol, was reported by
Tabakoff (12).

The conflicting results reported on this subject

are suggested to be due to the functional differences of 5-Hr metabolism in the periphery and CNS (11).

NE and DA have not been

studied centrally with regard to the effect of ethanol metabolism.
Various explanations have been suggested for the effect of
alcohol on peripheral CA metabolism: inhibition of monoamine
oxidase·(MAO) (13); a depletion of nicotinamide adenine dinucleotide (NAD, oxidized from, and NADH, reduced fonn) with a resultant
increase of NADH/NAD ratio due to the oxidation of ethanol (8,12),
and finally a competitive inhibition between AcD (derived from
ethanol) and the intennediate biogenic aldehydes (MAO products) for

I'··'·
-4-

the K;ti'Vflt sitlit on· aldehyde dehyd1:0genase (8, 14).

Recently,

supporting evidence for the competitive inhibition hypothesis has
been reported (15,16).

It was shown that AcD in the presence of

excess NAD still caused a decrease in the formation of

14

c-5-HIAA

with a simultaneous increase in the neutral fraction (presumably
5-hydroxy-tryptophol) in rat brain homogenates (17).
II. EFFECT OF ETHANOL AND ACETALDEHYDE ON NEUROAMINE STORAGE AND

RELEASE PROCESSES.
Ethanol has been reported to increase urinary epinephrine (E)
and NE levels in the rat (18).

Klingman et al (19) reported that

an acute sublethal dose of alcohol in dogs produced a marked in.crease in urinary E and NE.
was decreased.

After adrenalectomy, only E excretion

These workers found that ethanol lowers the adrenal

content of E without a significant effect on NE content•

The main

emphases of the above experimental works have been concerned with
the action of ethanol on the storage and release of E from the
adrenal medulla and depletion of NE from sympathetic adrenergic
nerves (19).
In humans, ethanol consumption has been shown by several investigators to increase the release and excretion of CAs (20,21,22).
Alcoholics who showed withdrawal symptoms in controlled intoxication studies continued to excrete larger amounts of urinary E and
NE, whereas in those alcoholics not showing withdrawal symptoms
the urinary CA concentrations returned to prealcohol baselines(21).
This increase in urinary excretion of NE and E following cessation
of ethanol intake in alcoholics during withdrawal appears to be

-5-

a.ssaciated vdt.h a

~neralized

activation of the sympathetic nervous

system (22,23).
Some investigators very early suggested that the release of
neuroamines by ethanol.might well be due to its metabolites rather
than, or in addition to, alcohol.

Perman (24) found that i.v.

injection of AcD in the cat produced a marked increase of E and NE
levels in the suprarenal venous plasma.

Therefore he suggested that

AcD derived from ethanol may be the active agent responsible1 for the
increased level of the urinary CAs.
'•

Using purified adrenal prepara-

tions, Akabane et al (25) were able to show that AcD intensifies
the secretion of both E and NE from medulla.

They indicated that

CA release was closely correlated with an action of AcD on the
membrane storage sites.

Walsh and Truitt (26) reported that after

i.v. administration of 3H-NE in cats and rabbits, AcD produced a
much larger and more innnediate release of the neuroamines into the
plasma from peripheral nerve terminals than did ethanol.
CNS stores of biogenic amines also have been studied in regard
to the effect of ethanol and in general the findings are controversial.

Gursey et al (27) and Gursey and Olsen (28) found that i.v.

administration of ethanol produced a significant reduction in rabbit
brain stem 5-IIT and NE.

They felt that the effect of ethanol

resembles that of reserpine in action, because they found that the
reduction in central amine stores lasted several days.

Other

investigators have not found any effect of ethanol on the brain
content of the amines (30,31,32,33).

However, Corrodi et al (29)

could demonstrate an alcohol-induced decrease in rat brain stem NE

-6-

iu tha ahsenca of compensatmiey: GA synthesis, by administration of
c1t~methyl-p-tyrosine,

a tyrosine hydroxylase inhibitor.

Duritz and Truitt (34) suggested that this discrepancy may be
because AcD is responsible for this effect.

Intraperitoneal (i.p.)

administration of AcD or of ethanol plus disulf iram induced a
decrease in rat and rabbit brain NE, which was not seen with acute
ethanol alone.

They concluded that differences in brain amine

liability to AcD, as well as the required time for maximal blood
AcD levels after ethanol ingestion in different species, were crit'•

ical factors.
III.

FORMATION OF ALKALOID CONDENSATION PRODUCTS FROM NEUROAfIINES
AND ALDEHYDES.

During ethanol metabolism the level of AcD, chemically a very
reactive substance, increases in body fluid and cells.

Table l

demonstrates various biochemical substances which can easily react
with AcD.

A non-enzymatic condensation reaction has been shown to

occur readily at physiological conditions between the amino groups
of B-aryl ethylamines and carbonyl compounds, including AcD, to
form varieties of cyclic compounds, B-carbolines in case of
indolamines (tryptamine and 5-HT) and TIQs in case of m-hydroxylated phenethylamines (NE, E, DA).

a.

Simple TIQs (1-alkyl-TIQs)

CAs

In 1970, Cohen and Collins (1) reported that TIQ biosynthesis
takes place in the medulla of isolated
lowing perfusion with dilute AcD in
(pH 7) at 37"C

cow adrenal glands fol-

isotonic phosphate buffer

Later Cohen (44) confirmed TIQ formation in
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TABLE 1
Known chemical reactions between acetaldehyde and biological substrates - Modified from M.J.Walsq(35)

Reactant

Product

Reference

A) Pyruvate

Acetoin

(36)

O<- ketoglutarate

5-hydroxy-4-ketohexanoic acid

(37)

B) Coenzyme A (Co A)

Semi mercaptal formation; reported to
decrease brain and liver levels of active
Co A

(38)

C) Various amines
1. Indolamines
5-methoxy-tryptamine
tryptamine and 5-HT
2. Catecholamines (CA)
epinephrine (E)
norepinephrine (NE)
dopamine (DA)

presumed Schiff base formation
(39)
B-carbolines
(40)
10-methoxy-harmalan
(41)
1-methyl-harmaline
1,2,3,4-tetrahydroiso-quinolines (TIQs)
l,2-dimethyl-4,6,7-trihydroxy-TIQ (gigantinol*)( 1)
1-methyl 4,6,7, trihydroxy- TIQ
( 1)
l-methyl-6,7-dihydroxy-TIQ (salsolinol)
(42)

D) Amino acid: DOPA

~

,,

1-methyl-3-carboxy-6,7-dihydroxy-TIQ

* This compound is hereafter referred to by its trivial name gigantinol, which is derived from the
name ascribed to its 6,7-dimethoxylated isomer, the only isolated 4-hydroxy-TIQ, gigantine (from
Carnegia Gigantea) (120),

-8·~

(43)

~;-

,,

the perfused adrenal gland at phy~iological (1-2 ug/ml) concentra14
tions of
C-Acll. The presumed reaction sequence of TIQ formation
is presented in Fig.2.
Formaldehyde (HCHO)-derived TIQ biosynthesis was promoted in the
rat adrenal glands during

14

c-methanol metabolism (45).

They

observed the presence of the radioactive TIQs by thin layer chromatography, while E and NE were not radioactive.

Further evidence

for TIQ synthesis in vivo was obtained by Cohen and Barrett (46),
who reported that TIQs were detected by fluorescence microscopy in
lyophylized slices of adrenal tissue taken from rats chronically
intoxicated with non-radioactive methanol.
Robbins (47) reported on the chemical reaction capability of
several biogenic amines with AcD and suggested that such a reaction
might occur in extracellular body fluid after ethanol ingestion.
Yamanaka and coworkers -,, (42) observed salsolinol formation in the
homogenates of rat brain, stem and liver incubated with 14 c-DA and
AcD.

Based on these findings, Cohen and Collins (1) and Yamanaka

et al (42) have suggested that physical dependency and 'withdrawal
symptoms of alcoholics may be partly related to the formation of
simple

T!Qs

in nerve tissue.
b. CAs

-----.

Benzylisoquinolines

Holtz and coworkers (48) originally described in vitro condensation of DA with its aldehyde, 3,4-dihydroxy phenylacetaldehyde,
resulting in the formation of the 1-benzyl-TIQ, tetrahydropapaveroline (THP).

Davis and Walsh (2)

showed in vitro that AcD

inhibits aldehyde dehydrogenase activity and leads to the accumula-
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r
OH

OH

R' CHO ·

,

R= H; norepinephrine (NE)
R=CH ;epinephrine
3

4,6,7-trihydroxy-1,2,3,4-

R=H; CH3

(E)

Tetrahydroisoguinoline

"

HO

+

HO

HO
R' CHO

R'

Dopamine (DA)

6,7-dihydroxy-1,2,3,4Tetrahydroisoguinoline

~
.~

R= CH3 ; salsolinol
Fig. 2

Formation of tetrahydroisoquinoline (TIQ) alkaloids.
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~

u 9n

of 3,4-dihydroxy

phenylacetaldehy~e.

This latter metabolite

eondenses with the second molecule of DA, and THP is formed ( Fig. 3).
THP h.8s been reported to be an intermediate compound in the biosynthesis
of morphine (81).

This had led Davis and Walsh to suggest (2) that

alcohol addiction may be associated with the formation of this TIQ
alkaloid.

They reasoned that the formation of THP in brain tissue with

relatively low aldehyde dehydrogenase activity is more likely than in
other tissues which have high aldehyde oxidizing capacity.
It also has been stated that NE reacts with its biogenic glycol;

·. aldehyde to form the analogous dihydroxylated THP (35).

Similarly, a

condensation product of 5-HT and its aldehyde was indicated by thin
layer chromatographic (TLC) analysiS, Thus, complex alkaloid formation
appears to be a general reaction in vitro in the presence of MAO (35).
Sandler and coworkers (49) recently provided support for the
hypotheses of simple (1) and complex (2) TIQ formation by detecting
salsolinol and THP in the urine of Parkinsonian males who had been
treated with therapeutic amounts of L-DOPA.

Ethanol administration

increased the level of urinary salsolinol in these patients.
c. Indolethylamines -

B-carboline alkaloids

Taborsky and Mcisaac (41) performed extensive experiments in an
attempt to isolate pure B-carbolines from the reaction of a number of
tryptamine derivatives with AcD.

They were unsuccessful in isolating

a single purified product from serotonin and AcD reaction.
the impure

products

they

obtained
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from

this

amine

However,

proved to be

HO·~cooH..

3,4-dihydroxyphenylacetic acid

HOJV

HO

HO

HO

HO

..

3,4-dihydroxyphenylaceta}.dehyde

Dopamine (DA)
'•

HO

HO
HO

Tetrahydropapaveroline

HO

(THP)

NH
HO

HO

0

I
I

H

'II

•

NR

Normorphine, R=H
Morphine,
R=CH
Fig. 3

3

Schematic representation of hypothesis illustrating an alteration
in the metabolic disposition of DA produced by Ethanol (~)
with the postulated resultant formation ~£ complex alkaloid
derivatives.
From V.E. Davis and M.J. Walsh (10).
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potent MAO inhibitors and 5-HT antagonists and promoted aldosterone
secretion. These are properties characteristic of B-carbolines.
Later Mcisaac (40) reported the isolation of small amounts of 1-methyl6-methoxy-tetrahydro-B-carboline in the urine of rats treated with.
ethanol, 5-methoxy-tryptamine, iproniazid (MAO inhibitor) and
disulfiram (aldehyde dehydrogenase inhibitor).

This finding points

out the possibility of a reaction such as the one depicted in Fig.4
to occur during alcohol ingestion in the pineal gland, a good source
of 5-methoxytryptamine.

Also very recently, Dajani and Saheb (50)

'•

isolated and identified l-methyl-6-hydroxy-B-carboline from the
urine of rats that were injected with ethanol and 5-hydroxy-tryptophan
plus inhibitors of MAO and aldehyde dehydrogenase.
IV. CONDITIONS MODIFYING AMINE-ALDEHYDE

CO~"'DENSATIO~~S

The capacity of a .reaction occurring between AcD and almost every
amine has been demonstrated.
formation of TIQ alkaloids.
the two major factors.

Several manipulations could promote
Increasing amine or aldehyde levels are

Amine levels may be increased by inhibiting

MAO oxidation, as was done with indolamines (vide suora), or possibly by inhibition of catechol-0-methyltransferase (COHT) methylation.

Inhibiting AcD metabolism is a way of enhancing this reactant's

concentration.

Therefore, by increasing the AcD levels as well as by

elevating CA levels, theoretically the formation of TIQ alkaloids
would be promoted.

Since CA derived TIQs are good COMT substrates(51,

52), inhibition of 0-methylation may favor the detection of catechol
TIQs.

In the case of THP formation, it presumably can be promoted by

any drug that competitively inhibits aldehyde dehydrogenase in tissue.
;r, \
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Fig. 4

Proposed pathway for the formation of B-carboline alkaloids
from indolamines,modified from W.M. Mcisaac (40)
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V. RELEVANT PHYSIOLOGICAL AND PHARMACOLOGICAL STUDIES ON TETRAHYDROISOQUINOLINES .
,
· Early pharmacological research on simple TIQs has been discussed
(53,62).

More recently it has been noted that simple TIQs in vitro

are accumulated by rat iris (54).

This accumulation could be

blocked by desmethylimipramine (an inhibitor of CA uptake).
llarly,

~IQ

Sim-

uptake by central catecholaminergic nerve terminals and

inhibition of CA uptake have been reported.

Cohen et al (55)

observed that accumulated radioactive CAs in rat brain homogenate
were released by salsolinol incubation.

Simple TIQs derived from

'•

E and NE, biosynthesized in AcD-perfused cells, could be released
by sympathetic stimulation (56).

These findings indicate that TIQ

alkaloids share the same transport ..and/or storage
nervous system and adrenal as the CAs.

in the

Therefore, Cohen (57) has

suggested that TIQs might be capable of acting as
transmitters.

sit~~

11

false" adrenergic

TIQs of the salsolinol type -have been shown to have

both central and peripheral pharmacological effects (58,59).

These

alkaloids may have either CNS depressant or stimulant and convulsant
properties (58,59), lypolytic activity (60,61), and various effects
on smooth muscles (59).
As discussed by Collins (63), very few simple alkaloids possessing a hydroxy group at the 4-position on the TIQ ring are known to
occur naturally, and no physiological studies have been done on
synthesized compounds analagous to those formed from the condensations of E and NE with AcD.
I

Recently, however, some evidence has

been obtained suggesting that 4-hydroxy-TIQs may be key intermediates
in the bio.syntheses of several classes of complex alkaloids (64).
-15-
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On tbe other hand', THP has been more fully investigated.

Some

of its pharmacological effects on respiration, blood pressure and
smooth muscle were described in 1910 (65).

This alkaloid is

sympathomimetic (65), evoking positive inotropic and chronotropic
responses and decreases in blood pressure with accompanying
increases in peripheral blood flow (10).

In addition, relaxation

of isolated smooth muscle preparations such as uterus, intestine
and trachea is produced by THP (66). Furthermore, mobilization of
lipid both in vivo (67) and in vitro (68) is enhanced by this

·.

alkaloid.

All of the pharmacological effects reported for THP can

be prevented by

B-adrenergic blockl.ng agents (65,66,67,:68).

VI. THE POSSIBLE INVOLVEMENT OF NEUROAMINE-DERIVED ALKALOIDS IN
ALCOHOLISM.
Ethanol directly or indirectly affects neuroamine metabolism,
but the significance of these effects in relation to physiological
and behavioral aberrations in alcoholism has not been defined.
However, there are several theories proposed to account for the
above-mentioned abnormalities found in human alcoholism.

Several

groups of workers believe that the condensation products of biogenic
amines and aldehydes may be important metabolites in the utilization
of ethanol.

The first general hypothesis related to this topic

came from Mcisaac (40).

In 1961, he put forth a general biochemical

concept of mental disease.

He suggested that normally circulating

AcD in the body may condense with 5-methoxy-tryptamine (O-methylated
serotonin) to form 10-methoxy-harmalan, a potent serotonin antagonist
and MAO inhibitor.
-16-
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Cohen and Collins hypothesized (described in part I) that, due
to the ease of biosynthesis of TIQ alkaloids in adrenal tissue during AcD perfusion, the possibility of TIQ formation at adrenergic
fibers of the sympathetic nervous system and brain is likely (1).
If so, the TIQ alkaloids, either actively secreted or leaked from
nerve termini, could contribute to the behavioral changes observed
in alcoholic people.

They also suggested that the· signs of physical

dependence such as tremulousness, hallucinosis and seizures which
occur when concentrations of alcohol in blood (and brain) are falling
may be due to persisten physiological actions of TIQ alkaloids.
Amit and Stern (69) suggested that NE-derived TIQs were synthesized in the nervous systems of their experimental rats.

The

animals were made alcohol dependent by electrical stimulation of
the lateral hypothalamus.

Free cluice of alcohol consumption by

increasing the concentration of alcohol daily permitted the inges.tion of significant volumes of alcohol.

A reasonable model was

proposed for the role of TIQ thought to be formed in the synaptic
gaps by interaction of AcD with NE.

Increased precursor NE levels

were suggested to occur due to the electrical stimulation.

NE-

derived alkaloids would be taken up by the same presynaptic cells
from which the NE was initially released.

As a result, the pre-

synaptic cells involved would adapt to this new TIQ substance and
it gradually would become the neural transmitter for that part of
the nervous system.

Once adaptation to alkaloid is complete, the

neural system presumably cannot function well without it.

Thus,

the system would require regular intake of alcohol in order to
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fuaction.

Earlier

investi~:

(7Q.,.71) had brought out the same

sort of hypothesis suggesting that alcoholics may have an impaired
sympathetic nervous system which may be normalized by ethanol.
Davis and Walsh (2) have put forth the possibility of THP formation in the CNS and its involvement in the disease of alcoholism,
although this theory, like the simple TIQ hypothesis, is controversial (72,73).

These workers demonstrated the augmentation of THP

biosynthesis when ethanol or AcD and DA were incubated with brain
or

·.

liver homogenate.

Furthennore, it is known that in

plant~

THP

is a natural biosynthetic intermediate in the synthesis of morphine
alkaloids (81).
It should be added that indirect support of addictive TIQ formation was reported by Sprince and coworkers (74).

These investigators

found that, compared with controls, rats on a diet supplewented
with DOPA tend to prefer an ethanol solution to water.
VII. ANIMAL MODELS OF ALCOHOLISM
Induction of alcohol addiction in laboratory

ani~2ls,

to provide

a model to study the neurochemical aspects of alcoholism, is particularly important ( 137, 138)
Numerous workers have attempted to produce signs of physical
dependence and subsequent withdrawal syndromes with ethanol in a
variety of animals.

Very little success has been achieved in

inducing ethanol withdrawal syndromes in animals by the voluntary
drinking of aqueous ethanol solutions.

In rodents, usually most

ethanol is consumed during the night, leaving the daytime for
recovery.

But Freund (75) found that 1 iquid diet in which
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35~~

of

cad:O'ries came from ethanol produce<l: physical dependence in mice
within four days.

Ellis and Pick (76) developed an alcohol

intubation method that produced human-like withdrawal symptoms in
monkeys and dogs that could be suppressed by ethanol administration.
Recently Majchrowicz (77) has reported alcohol dependence in rats
after eight days

~f

gastric intubation. Pieper et al (78) recently

found that young chimpanzees voluntarily consuming ethanol demonstrated withdrawal symptoms similar to those observed in humans.
Goldstein's method (79) of inducing physical dependence involves
closed chambers in which mice breathe ethanol vapor.
VIII.

GAS CHROMATOGRAPHIC DETERMINATION OF CATECHOULHNES

In gas chromatographic (GC) analysis, it is often necessary to
prepare derivatives of substances to be analyzed.

The aim of deriv-

ative formation is to increase the volatility of the conpound and to
reduce its polarity.

In addition, derivative formation

r.3y

give

information by causing changes in retention time (80,99).
GC analysis, potentially as sensitive as fluorometry, may be the

most specific method available for the estimation of biological
amines.

With electron capture (EC) detectors, as little as lo-12

grams (picogram) or less of some compounds can be detected, but this
requires certain halogenated derivatives which are good electrol
acceptors.
GC analysis of CAs have been done by a number of groups using

trimethyl-sylyl derivatives.

Horning et al (82) published a

method of O, N-trimethylsilyl formation of CAs with trimethylsilyl
imidazole and bis-trimethylsilyl acetamide.
-19-

Fluoroacyl deriva-

tives of CAs for EC detection recently have been employed by the
workers in the field.

Recently Arnold and Ford (83) prepared

different fluorinated derivatives of CAs using trifluoroacetic
(TFA) anhydride, pentafluoropropionic (PFP) anhydride and
heptafluorobutyric (HFB) anhydride in acetonitrile.

HFB deriva-

tives showed the highest sensitivity of the three.

They measured

CA levels in rat brain tissue.~.artin and A..~sell (84) reported EC/
GC estimation of DA, NE, and 5-iIT in rat brain using TFA-anhydride

in acetonitrile.

Koslow and coworkers (85), using mass frag-

mentography, a technique in which the mass spectrometer is used as a
single or multiple ion chromatographic detector, assayed
in 0.1 mg tissue in the picomole range.

and DA

NE

They used PFP-anhydride

in ethyl acetate as a derivatizing agent.
IX. GAS CHROMATOGRAPHIC DETE&.'1Il1ATION OF TETRAHYDROISOQUeOLDiE

ALKALOIDS.
Only a limited number of TIQ studies have been er:-ployed using
GC methods.

Agurell (86) has carried out GC studies on TIQ plant

alkaloids with

a flame ionization (FI) detector.

Cashaw et al

(87) developed a flame ionization GC method for determination of
TIQs including salsolinol and THP in urine.

They have used

trimethylsilyl derivatives which are not applicable for EC
tors.

d,~tec-

More over, this work was not applied to the study of endoge-

nous amines in tissue.

Sandler et al (49) performed EC-GC analyses

of the urine from Parkinsonian patients for the detection of
salsolinol and THP, employing PFP derivatives.

This work was not

concerned with the simultaneous separation and measurement of CAs
and TIQs.
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PART TWO

EXPERIMENTAL SECTION
A.

MATERIALS
I.

CHEMICALS
Derivatizing agents (HFB anhydride, PFP anhydride, sylilation

grade acetonitrile) were purchase:! from Pierce Chem.ical Company.
of these reagents were kept refrigerated.

All

Ethyl acetate (Pierce

Chemical Company) was distilled before use. L-(-)-E and L-(-)-NE
were obtained from Regis Chemical Company.

The hydrochloride salts

of metanephrine and normetanephrine were purchased from Winthrop
Laboratories.

Salsolinol hydrobromide was obtained from Aldrich

Chemical Company.

The hydrochloride salts of 4-hydroxy-TIQs were

synthesized in our laboratory (88).
our experiments are shmm in Fig. 5.
from Wel:ome Laboratories, England.

The structures of those used in
THP was obtained as a gift
Aluminum oxide (A1 2 0 ) (Woelm,
3

neutral activity grade) was activated by the procedure of Anton and
Sayre (89) and was stored in a desiccator over drierite.

Perchloric

acid and sodium metabisulfite (J.T. Baker Chemical) were c.p. grade.
Bitartrate salts of radioactive CAs (14c-DA, 14 c-E) were obtained
from Amersham/Searle.

All solvents for scintillation counting were

purchased from Beckman Chemicals.
II.

ANilIALS
Male Sprague-Dawley rats (Holtzman) weighing 350 ± 20 grams were

used in all experiments with the exception of the pyrogallol/methanol
experiment (vide infra).
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OH
HO

CH

CH

1-methyl 4,6,7trihydroxy-TIQ

3

3

1,2 dimethyl-4,6,7trihydroxy-TIQ (gigantinol)
HO

( ff 1 )

( ff 2 )

HO
CH

3

1-methyl-6,7-dihydroxyTIQ (salsolinol)
HO

OH
HO

OH

(if 3)
'•

HO

HO

4, 6 ,7~ trihydroxy-TIQ

2-methyl-4,6,7-trihydroxyTIQ (1-norgigantinol)
HO

( ff 4 )

( ff 5 )

6,7-dihydroxy-TIQ
OH

(if 6)
CH 0

3

HO
CH

6-methoxy-4,7-dihydroxyTIQ

1-methyl-6-methoxy 3
7-hydroxy-TIQ

( ff 7 )
( ff 8 )

(ifa 9)

Tetrahydropapaveroline
(THP)

Fig_. 5

1,2,3,4-tetrahydrois<;>quinolines (TIQs) used in these studies
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III. GAS CHROMATOGRAPHY
The analyses were performed on a Varian Model 2100 GC instrument
equipped with electron capture (EC) and flame ionization detectors
and injection port extenders.
on a direct current mode.
grade, Liquid Carbonic).
6 feet) were used.

The 63Ni-EC detector was operated

Carrier gas was nitrogen (Nz) (zero
U-shaped glass columns (1/8 inch i.d. X

All column packings were prepared in our

laboratory using a solvent evaporation technique with a rotary
flash evaporator (90).

·.

The basic solid support was 80/100 mesh

Gas Chrom Q (Applied Science Laboratories) coated with various
liquid phases: SE-30, Silar, SE-54, OV-17, GE XF-1105 (Applied
Science Laboratories), SE-52 (Varian Aerograph), and Dexil 300
(Regis Chemical Company). Carbosieve 60/80 mesh (Supelco, Inc.) or
Porapak QS 80/100 mesh (Water Associates, Inc.) were employed for
ethanol and AcH determinations.

Columns were conditioned at their

maximum temperature for 24-36 hours with a

Nz

flow rate of 20 ml/

.min.
B.

METHODS
I. PREPARATION OF FLUOROACYL DERIVATIVES
To 1 mg of the catechol compound in 5 nl screw capped vials,
0.1 ml acetonitrile and 0.2 ml HFB anhy]ride or PFP anhydride were
added.

To each sample of tissue extract a total of 0.2 ml aceto-

nitrile plus 0.4 ml HFB anhydride was added.

Each vial was covered

with aluminum foil, capped, and left at room temperature.
30-60 minutes the solution was dried under a N2 stream.

After
The vial

was then tightly capped and stored at-20~C until used ~for GC
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analysis.

Dried derivatives obtained in this way were redissolved

in distilled ethyl acetate to the appropriate concentration prior
to analysis.

TIQ #1 and #2 (Fig.5), which were not available as

crystalline compounds, were prepared by the method of Cohen and
Collins (1) by condensation of AcD with NE and E respectively, and
were then derivatized following lyophilization (vide infra).

THP

fluoroacyl derivatives were prepared from the hydrochloride salt,
which was made by dissolving 5 mg THP base in 2 ml 0.05 N HCli in
methanol ( 1 : 99 v/v) and evaporating the solution with a N2
stream.

0-methyl metabolites of CAs and TIQs were derivatized in

the same manner.
II.

PREPARATION OF CALIBRATION CURVES
In order to determine quantitative measurements and linearity

of detector response to catechol compounds, calibration curves were
constructed by plotting the peak height versus picogram (pg)
·substrate.

A stock solution (1 mg/ml in ethyl acetate) of each

derivative was prepared.

In the case of TIQ ffl and TIQ il2, the

concentration of each calibration solution was based on the weight
of parent amines (E and NE) before reaction.

In the situation where

the peak areas were measurable, the calibration curves were also
prepared by plotting the peak area (planimetric method) versus the
concentration, thus permitting comparison of data by two measurements.
Calibration curves were determined for each experiment, in order to
guard against changes in EC detector response to a particular amine.
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III.

EXTRACTION OF CATECHOL COMPOUNDS FROM TISSUE
The entire extraction procedure is sunnnarized in Fig. 6.

Each

sample of tissue (either whole brain, combined brain parts or pair
of adrenal glands) from a single rat was weighed, transferred to a
5-ml conical homogenizing tube (Kontes Glass Company) containing a

2 ml mixture of 1 N perchloric acid and 0.05 M sodium metabisulfite.
The sample was homogenized for five minutes while the tube
immersed in an ice-cold bath.

was

All centrifugations were done in the

cold room (4°C) in a clinical centrifuge.

The homogenate was

centrifuged at 2,000 rpm for 15 min. and the resulting supernatant
was removed with a Pasteur pipette and was transferred to a 15-ml
screw-capped vial.

The precipitate was rinsed with another 2 ml of

the homogenizing media and was centrifuged as previously described.
Both supernatants were pooled and saved, and the precipitate was
discarded.

14 c-DA (purified with Al o prior to use) was added to
2 3

the supernatant obtained from brain homogenate in order to determine
the percent recovery.

10% of the total brain homogenate was

examined by scintillation spectroscopy, while the remaining 90
percent of the supernatant was used for Al 2 o3 extraction of catechol
14
compounds. Purified
C-E was added to the adrenal homogenate for
the same purpose and the same steps were followed.
IV.

Al20 3 CATECHOL EXTRACTION PROCEDURE
The pH of the supernatant (above) was brought to between 6-7 by

.the addition of 1 N NaOH.

Activated Al 2 0 3 (100 mg) was added and pH

was adjusted to 8-8.2 by careful addition of 0.2 N NaOH.
was shaken with a mechanical shaker for ten minutes.
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T~e

The mixture
Al 2o3 was

Experimental or control
rat

•

Brain, brain parts or adrenal
tissue (1 N HC104 + 0.005%
Na 2s 2 05)

G.C. monitoring of ethanol
and AcD blood levels

1

1
Discard precipitate

homogenize
centrifuge

Supernatant

..------------------ij add

1

l

10% of aliquot for
scintillation counting

14

l4c-DA or

c-E

90% of Aliquot

J

Al203, pH 8.0-8.5
shake 10 min

i

Al 20 3 and bound material;
wash three tiwes with
distilled water

Supernatant for assay
for 0-methyl-CAs

!

0.1 N HCl

.--~~~~~~~~~~~~~~---ijshake 10 min

J

!

Supernatant
lyophyl iza tion

!

Fluoroacylation in
acetonitrile
!evaporation with N2
Residue
r-~~~~~~~~~~~~~~~Jdissolve in Ethyl acetate

!

I

Take 50% of aliquot for
scintillation counting

1

EC/GC analysis

I

Fig. 6
General Procedure for the Isolation of Tissue Catechols with
Activated Aluminum Oxide (Al 2 0 3 ) and their derivatization for EC/GC
analysis.
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allowed to settle and supernatant was transferred to another test tube
with a Pasteur pipette and stored in the freezer for subsequent analysis of phenolic CA metabolites.

The Al 0 3 portion was washed with
2

three 5-ml portions of distilled water.
then eluted from A1

o

2 3

The catechol compounds were

by shaking for ten minutes with 2 ml 0.1 N HCl.

The Alz0 3 was discarded and the acid supernatant was lyophylized.

The

dried residue was stored at-zooc for later derivatization.
In some instances, a prior purification step was done on brain
homogenate.

Fatty substances were removed (91) by ten volumes of a

mixture of organic solvents (ether-benzene 5:2) added to the supernatant portion of the homogenate.

The aqueous layer was then processed

through the Alz03 purification procedure.
V.

ION EXCHANGE COLUMN

CHRO~·!l1.. TOGRAPHY

OF PHENOLIC Cl\

~fETABOLITES

Dowex AG50-WX (50 gm) was washed four times with distilled
water and acidified under the flow of eight liters of 2N HCl passing
dropwise through a column.

The acidified Dowex was brought to neutral

pH in the same column with distilled water.
The Dowex, stored under distilled water, was poured into a 4 mm
i.d. narrow-tip column until a packing height of ca. lcm

was obtained.

The supernatant from the Al20 3 extraction (the solution containing
phenolic CA metabolites) was passed through the column after adjusting
the pH to 3;5 with phosphate buffer (0.1 M KHzP0 4
The column
water.

was

washed

The adsorbed

with

four

materials

2 - ml
were.
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then

+ 0.1 M NaOH).

portions
eluted

of
with

distilled
2 ml

o:f. a: 1: 1 mixture of 6N. HCl.: absolute ethanol (v/v) (121), and the
eluant was lyophylized and stored in the freezer for future derivatization.
VI. QUANTITATIVE AND QUALITATIVE MEASUREMENT OF PFP AND HFB
DERIVATIZED CAs AND TIQs
Since the linearity of the EC detector is limited, the concentration of the HFB or PFP derivatives in ethyl acetate was adjusted to
be in the range of pg/ml.

However, a problem arose in the quantita-

tion of the suspected TIQ alkaloids in the tissue of the alcohol
treated animals, since they were present in such minute concentrations.

This necessitated the injection of a concentrated solution

of the derivatives, which precluded obtaining precise quantitative
results.

In previous work (53) it was observed that HFB derivatives

were not stable at room temperature in ethyl acetate long enough to
complete both quantitative and qualitative measurewents on all samples, especially when these -investigations require changing GC
columns (which then take 12-16 hr to become equilibrated!.
Therefore, when the catechol compound from each rat's brain parts
or adrenals were extracted and derivatized, the resulting soluti8n
was divided into two portions (10% and 90% v/v).
under a tream of
analysis,

was

Nz.
stored

Both were dried

The larger portion, to be used for qualitative
at-20°c.

The smaller

portion

was

dissolved in 5 ml ethyl acetate.

One ul of this diluted solution

was

CAs by

analyzed

quantitatively for

EC/GC

at 4 to 8 x lo-lO AFS electrometer settings.

(GE

XF-1105)

Peak heights were

measured and the concentrations of CAs or their metabolites (un-
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corrected for recovery) per g tissue were calculated using the
calibration curves.

In the third pyrogallol/acute ethanol exper-

iment (Results, vide infra), adrenal CAs were determined per g
protein as well as per g tissue.

Adrenal protein was measured

spectrophotometrically by the method of Lowry (122).
The larger portion, used for qualitative analysis of potential
TIQs at 1 to 4 x 10-lO AFS and for radioactive recovery, was
dissolved in 1 ml distilled ethylacetate.

Approximately 500 ul

of this solutin was utilized to determine overall recovery by
scintillation spectroscopy (representative calculation in Fig.7),
and 1 ul portions of the remaining sample were injected on the GC
column (3% OV-17).
VII.

QUANTITATIVE ANALYSIS OF ACETALDEHYDE AND ETE.•\XOL 2:.X BLOOD

The estimation of AcD and ethanol levels in blood during
chronic and acute alcohol intoxication was done by flane ionization
GC, modifying the method of Coldwell et al (92) .

Tail blood was

sampled four times during acute intoxication (timing is

sumrr~rized

in Fig. 11) and once at the end of the chronic intubation ezperiment (two hours before sacrifice).

For each sample, 20 ul blood

was transferred by a heparinized micropipette onto a sodium
fluoride impregnated paper disk in a 30-ml serum bottle
quickly stoppered and kept in ice.

::~:.idi

uas

Before injectint the sample into

the bottles were shaken at 35° C in a thermostatic metabolis shaker
for 15 minutes to equilibrate the released gases.

Aliquots of 1-2 ml

head space gas from the serum bottle were injected on the GC column
by means of a gas-tight syringe.
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~upernatant

from tissue
homogenate

+
ca. 10.000 counts/min
14c-DA (or 14c-E)

!

l
90%

(A) 10% aliquot- count/min

J

extract and

--~~~~~~~~~~

i
(B)

5%

aliquot - count/min

Recovery=

50% -

2B x 100
9 A

Fig. 7

Calculation of % recovery
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derivatize
GC

analysis

a. Preparation of Calibration Curves
The calibration curves were prepared by dilution of aliquots of
stock solutions of ethanol and of AcD to known concentrations with
rat blood.

The final concentrations in the standard solutions

ranged from 0-3.0 mg/ml for ethanol and 0-80 ug/ml for AcD.

The

GC parameters were:
Barber Coleman Model 53ZO GC:
Column: Aluminum, 6 foot x

~

inch o.d. packed with Porapak QS

(80/100 mesh, Water Assoc.), conditioned for Z4 hr at 180° C.
Temps: Column= 145° C, Detector = 200° C
Flow Rates: N2, 100 ml/min; Hz, 30 ml/min; Air, 300 ml/min; and
Varian model 2100:GC:
Column: Glass, 3 foot x 1/8 inch i.d. packed with Carbosieve-B
·(60/80 mesh, Supelco Co.) conditioned for Z4 hr at 250° C.
Temps: Column = 175° C

Injector = Z30° C Detector

Flow Rates: N2 , 70 ml/min; Hz, 30 ml/min;
VIII.

= 250° C

Air, 300 ml/nin

ACUTE ETHAi.'{OL !-'fETABOLISH STUDIES

Acute intoxication experiments lasted eight hours
1000 hrs to 1800 hrs.

fros

In order to control for circadian rhyth::i

factors, this timing schedule was observed for all
experiments.

eac~,

short-tee~

Since it is known that the levels of CA.s in rat brain

fluctuate diurnally (93), any differences in CAs between experimental and control animals can be assumed to be due to the effect of
alcohol.
Drugs and alcohol solutions were prepared in 0.9% (isotonic)
saline solution and administered according to the following sched-

-31-

ules.

After decapitation, combined brain parts, consisting of brain

stem, caudate nucleus and midbrain, hypothalamus included, (or whole
brain, in the case of the acute ethanol and methanol experiments)and
rapidly frozen in liquid N or in dry ice.
2

Organs from each animal were

kept in small plastic bags (Whirl-Pak, Nasco) separately at-20°C until
homogenization.

The above procedures were performed in the cold in

less than three minutes.
(a)

Ethanol

Each rat received 3 g/kg of 25% (v/v) ethanol in isotonic saline i.p. at
1100, 1350 and 1600 hr, while each control rats each received equivalent
volumes of isotonic saline at these times.

Two hr after the last

injection, the animals were sacrificed and the organs were removed and
frozen.
(b)

Pvrogallol/Ethanol

In three different studies (December 12, 1972, December 30, 1972, and
June 23, 1973), a total of 33 rats were each treated i. p. with 250 mg/kg
pyrogallol in isotonic saline at 1000 hr.

The 18 experimental ani1:1als

were given three i.p. injections (3 g/kg each) of 25% ethanol solution
(see VIII, a) 60, 210, and 360 min after pyrogallol treatment.

Each of

the 15 remaining rats received 6 ml of isotonic saline i.p., in place
of ethanol.
(c)

DOPA/Pyrogallol/Ethanol

In this study, experimental rats were treated as in experiment (b), but
with two additional i.p. injections of 100 mg/kg 1-DOPA suspended
in
30

isotonic
and

150

saline
min

(4% w/v).
after

The DOPA

injections

were given

pyrogallol; control received equivalent
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vo'lumes of isotonic saline at these times.
(d) Pargyline/Pyrogallol/Ethanol
Rats were injected i.p. once on each of two consecutive days with
mg/kg pargyline in water (4% w/v).

100

On the second day, one hr after

pargyline at 0900 hr, all rats were treated as in experiment (b).
(e) Reserpine/Pyrogallol/Ethanol
Two groups of rats were injected i.p. with either 2 .5 !Ilg/kg reserpine
(Serpasil, CIBA, 2-cc ampoules of 2.5 mg/cc) or vehicle of Serpas11.
On the following day, all were treated with pyrogallol followed by
ethanol or saline as in experiment (b)
(£) Pyrogallol/Methanol

The method used with nine animals (550 ~ 30 g) was the same as in
Experinent (b), except that the methanol solution in experiment (g)
replaced the ethanol solution
(g) Me thano 1
Rats were given i.p. 3g/kg methanol in isotonic saline (30/, v/v) at
1200 hrs, followed by repeat injections at 1430 hr and 1700 hr.
Two hr after the last injection, they were sacrificed.

Controls were

treated with 3 ml isotonic saline at the same times.
IX. fHRONIC METABOLISM - "ALCOHOLIC" RAT STUDIES
In two chronic intoxication experiments, rats were treated by two
different routes (vide infra) with 25% ethanol (v/v)
for 15 days.
dai~y

Depending on the state of

in

water

intoxication of the animals,

amounts ranged from 8-12 g/kg usually

in

3

doses/day.

They were housed in individual cages and all had free access to
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water and, in the case o:fi th&- chironic i.p. experiment, lab chow·.
Ethanol was isocalorically substituted by 21% (w/v) dextrose solution in the control-animals.

During the e:Xperiments, food intake

and body weight were recorded.
Two different chronic intoxication studies were performed:

a. Gastric Intubation

In this method, ethanol or dextrose solution was administered by
gavage with a four-inch urethral catheter attached to a 10-ml
syringe.

The experiment was started with two intubations/day of

ethanol or isocaloric dextrose solution and raised on the 3rd day
to 3 intubations (3-4 g/kg) at 0100, 0900 and 1700 hrs, according
to Majchrowicz's procedure (77).

The average amount of food and

water consumed by the ethanol-treated rats was given to the controls
the next day (pair-feeding).

On the last (15th) day of this study,

tail blood samples were collected at ca 1500 hr, to measure the AcD
and ethanol levels 2 hr pre-sacrifice.
b. i.p. Injection
The conditions of this experiment were the same as above except for
the route of administration and the absence of pair-feeJing. In this
method, ethanol or dextrose solution was administered via i.p.
injection.

Along with the ethanol group, another group of rats was

injected with the 3g{kg methanol in

~vater

(25~~

v/v).

Food and

water were offered ad lib. Beginning on the fourth day of the treatments, the animals in both experimental groups began to die.

By the

xisth day, insufficient numbers of ethanol and methanol injected rats
were still alive, and therefore the experiment was discontinued.
-34-
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PART THREE

RESULTS
A. DERIVATIZATION OF CAs

A.~

TIQs

I. HFB-DERIVATIVES OF CAs AJ-..TJ) SIMPLE TIQs
In previous studies (53), a successful method for the EC/GC
analysis of TIQ alkaloids concurrent with their parent compounds,
CAs, was developed. Among different methods of derivation, the most
suitable results were obtained by 30-60 min reactions of the amines
at room temperature with HFB-anhydride in acetonitrile.

A single

derivative with a distinct retention time was obtained for each CA
and TIQ, using 3-5% OV-17 or SE-30 columns.

However, E and NE could

not be separated on these columns; others have reported this difficulty with TFA derivatives of E and NE on similar column packings
(94).

Also, .some difficulties with the detection and separation of

CA metabolites (0-methylated CAs ) existed when these liquid phases
were used.

Therefore, to improve the method, other liquid phases

such as SE-52, SE-54, Dexil, Silar and GE XF-1105 were checked at
different chromatographic conditions.
With a 5% GE

XF-1105 column, excellent separation of nearly all

the HFB-derivative.s of CAs and their derived TIQs and of phenolic CA
metabolites was obtained.

Fig.Sa

illustrates the retention times

and relative responses to the EC detector of the HFB-derivatives of

(SO pg each) DA, NE, E, salsolinol and 4,6,7-trihydroxy-TIQ, as well
as the 1-methyl-TIQ reaction products of E and NE with AcH.

Of

special note is the separation of E, NE and DA (HFB derivatives),
-35-
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which is. of significance. in adrenal. g)..a.nd analyses.
salsolinol were not separated on GE XF-1105.

HFB-DA and HFB-

Therefore a 3% OV-17

column, which readily separates these two derivatives, was used in
future analyses of brain extracts.
The minimum detectable quantity (MDQ),

i.e., the amount of

sample which gives a detector response equal to twice the noise level,
consistently was

smal~er

on 5% GE XF-1105 for most HFB-amines than

on any other liquid phase.

Unusua.lly sensitive were HFB-DA (NDQ= ·

0.5-1 pg) and HFB-salsolinol (MDQ=0.2-0.5 pg).
Fig. 8b is a chromatogram obtained by separation of 50 pg each
of several 0-methylated metabolites of CAs and TIQs on a 5% GE XF1105 column.
II. PFP-DERIVATIVES OF CAs

Ai~D

SIMPLE TIQs

Table 2 illustrates the retention times of the PF? derivatives
of some catechol compounds on different columns such as SE-52, SE-54
and GE XF-1105.

The relative EC detector responses to the PFP-

derivatives are shown in Table 2.

SE-30 and SE-54 were accep::able.

phases for resolution of a mixture of CAs and several TIQ derivatives
with appreciable sensitivity.

Overall, although direct comparisons

were not done, the HFB- derivatives appeared to show more than

40-601~

greater sensitivity to EC detection than the PFP derivatives, i.n
agreement with Arnold and Ford (83).
III.

DERIVATIZATION OF THP
Attempts to derivatize crystalline THP (free base) with HFB or

PFP anhydride in ethyl acetate or acetonitrile were unsuccessful
under the usual conditions.

However, the hydrochloride salt of THP
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Table 2
Retention times and EC/GC
1.

responses of PFP-derivatives of CAs and TIQs on various stationary phases

DA

3% SE-30

A

3.30

4.50

5.00

--

0.12

0.28

0.25

5% SE-52

A

4.10

2.45

--

6.00

0.20

0.25

--

0.18

5% SE-54

A

4.10

2.50

2.50

6.45

0.20

0.30

0.25

0.10

3io OV-17

B

4.20

2.30

2.30

6.45

0.15

0.20

0.18

0.15

5% GE XF-1105

c

7.40

9.10

5.15

7.40

0.10

0.25

0.20

0.10

Retention Time {min2
NE
E
Salsolino

1. On 80/100 Gas Chrom Q.
2. A: N2 Flow Rate= 30 ml/min; T = 160°c
B: N2 Flow Rate~ 30 ml/min; ·T = 170°c
C: N2 Flow Rate= 35 ml/min; T = 175°c
3. ng amines which give 50% deflection at 4 x 10 -lo AFS.
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)

l

GC
Conditions2

Stationary
Phase

DA

NE

Sensitivity)
E
Salsolinol

was readily derivatized with these reagents; the derivatives were
examined on different columns (Table 3).

Analogous to the other

catechol compounds, the HFB-derivative of THP demonstrated a greater
EC sensitivity than the PFP derivative.

Relative sensitivity and

retention times of the two fluoroacyl THP derivatives are shown in
Table 3.

It was observed thatPFP-THP sensitivity was strikingly low

on all columns, with an MDQ of 200-250 pg (or

sens~tivity,

as defined

in table 3, of 2-5 ng).
B. CALIBRATION CURVES FOR CAs A...'\fD TIQs
Calibration curves were constructed for DA, NE, E, salsolinol
and 4,6,7 trihydroxy TIQ on 5% GE XF-1105 following HFB anhydride/
acetonitrile derivatization.
(S.D.

= 8.5%)

The curves in Fig. 9 are the averages

of twelve sets of these calibration experiments.

Injection of a constant volume (1 ul of series of dilutions of
standards) resulted in peak heights proportional to the concentrations.

Such linearity could hardly be demonstrated with injection

of increasing volumes of a single standard.

Upper limits of lin-

earity ranged between 200-500 pg depending on the substrate.

This

upper limit was lowest for those compounds which demonstrated the
highest EC responses.

The calibration curves (not shown) for HFB-

derivatives of a-methylated catechols, 3-methoxy-tyramine, metanephrine, normetanephrine, 6-methoxy-4-7-dihydroxy-TIQ (#7 in Fig. 5 )
and l-methyl-6-methoxy-7-hydroxy-TIQ Ui=8 in Fig. 5)

were also

prepared using the same conditions as the catechol calibration curves
and were found to be linear up to 400-800 pg, depending on the substrate amine.

-39-

Table 3

A comparison of retention times and relative EC/GC sensitivities of fluoroacyl derivatives of
different liquid phases 1

HFB-THP
Retention Time(min)

PFP-THP
Retention Time(min)

Sensitivity 2

3% OV-17

7.40

5.2

8.55

4.0

5% SE-54

11.10

2.5'

16.10

2.0

3% SE-30

13.30

2.5

Stationary Phase

1

cc

Condition: Flow rate, 30 ml/min; column temperature, 190°C,

2ng amines which give 50% deflection at 4 x 10·10 AFS
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Sensitivity 2

40
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t::i..
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••<
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CONCENTRATION (P9/UI)
Fig. 9.EC/GC calibration curves for NE, E, the HCl salts of DA and 4,6,7,
trihydroxy-TIQ, and the HBr salt of salsolinol
GC conditions: 5% GE XF-1105; column temp. 175°c, N2= 35 ml/min
. Att.=4 x 10-10 AFS
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C. ExrRACTION AND RECOVERY
The extraction procedure described in experimental Fig. 6
involves the adsorption of catechol compounds on Al 2o and their
3
elution with hydrochloric acid.

This is a modification of the

method studied in detail by Anton and Sayre (89).
Previously it was found (53) that 100 mg activated aluminum
oxide was optimum for EC/GC determination (HFB-derivatives) of 1 mg
CA or TIQ in aqueous solution.

In these experiments this amount·was

determined to be adequate for the extraction of a pair of rat
adrenal glands or of one brain sample.
The highest recovery was obtained when elution of tissue CA
mixtures with added 14 c-DA or 14c-NE was carried out with 0.1 N HCl
and when derivatization followed the lyophylization of eluant (table
4). "Direct derivatization" involving HFB anhydride/accto:-iit:rile
treatment of catechols in the alumina-bound state was an alternative
acid-free procedure developed in M.S. degree research (53).

Those

original studies with non-radioactive substrates indicated that
recoveries were adequate.

However, recent experiments with 14c-

substrate showed that overall recoveries by direct derivatiz2t:ion
were about 10% (Table 4).

This direct derivatization method was not

improved or utilized further for tissue studies.
When aliquots of brain homogenate containing increasing asounts
of added NE, DA, salsolinol and

4,6, 7-trihydroxy-TIQ (tb4 in Fig.5)

were carried through the entire procedure of adsorption on aluminum
oxide and elution with 0.1 N HCl, followed by derivatization, the
calibration curves very similar to Fig.9 were obtained.Recoveries
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r
Table 4

% Recovery (mean ~ S.D.) of

14

c-CAs

1

following activated A1 o3 extraction and derivatization with
4
anltydride/acetonitrile

Direct derivatization of
lyophylized, Al?0 3 -bound CAs
No acid elutio~·
·

HFB~

Elution of CAs from A1 2 0 3 with 0.1
N HCl, lyophylization, and derivatization
CAs added to rat
CAs in lN HC10
brain homogenate

4

14C-DA

9.05

14C-NE
14C-E

1

*

14

C-CAs purified on A1

+ 0.80 (3)*

58.9 : 2.8 (3)

15.25

+ 0.65

87.1

11.46

+ 0.56 (3)

(3)

t

42.9: 4.1(9)

1.0 (3)

75.2 ±10.2(10)

•
o prior to.· their addition to aqueous solution or homogenate
2 3

Number of detenninations
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(foi:: 14c-CAs)

ft'ant

tissue agree with those from 1 N HC104 solution

(Table 4).
D.

EC/GC ESTIMATION OF CAs IN TISSUE
I.

BRAIN

The whole brains of four rats each analyzed on two different
columns (5% GE XF-1105 and 5% SE-54).

In Table 5 are shown our

results of these analyses, compared with the values determined by
other investigators using EC/GC and spectroflurometric methods.
II.

ADRENAL GIANDS
The CA concentrations in the adrenal glands of four rats, deter-

mined on 5% GE XF-1105, are shown in Table 6.

Our findings (Table

6) are compared with the results reported by Imai et al (95), who
also used an EC/GC method (TFA derivatizations).Literature values
for adrenal E determined spectrofluorometrically, somewhat higher
than EC/GC values, are also included in Table 6.
E.

BLOOD ETHANOL AND ACETALDEHYDE LEVELS IN VIVO
I.

CALIBRATION CuRVES
A Porapak QS column in a Barber Coleman 5320 flame ionization GC

was employed for the estimation of AcD and ethanol concentrations.
Using the microtechnique described in Experimental, two different
calibration curves were prepared on Porapak QS, one for AcD concentrations ranging between 0.5-5 ug/ml and a second curve for AcD
concentrations ranging from 10-80 ug/ml. A carbosieve-B column in
the Varian 2100 GC was unresponsive to low AcD levels but showed
sensitivity to the relatively high AcD levels (10 ug/ml blood).
Therefore, Carbosieve-B was used only to verify blood AcD identity
-44-

Table 5
Comparison of EC/GC and spectrofluorimetry (SF) estimations of CA concentrations in whole rat brain

Method

N

ug/g
NE

tissue

s ••
D

DA

Reference

EC/GC on 5% SE-54 *

4

0.55 ~ 0.08

0.90 + 0.07

this dissertation

EC/GC on 5% GE XF-1105**

4

0.46 t 0.08

0.99 +
- 0.09

this dissertation

EC/GC on 2% GE XF-1105

5

0.57

0.81

(95)

0.45 +- 0.01

1.00 +
- 0.08

(96)

0.45 +
- 0.01

0.96 + 0.01

(97)

SF
SF

*
**

10

GC conditions: column temperature, 1600C;N 2 flow rate, 30 ml/min
GC condition : column temperature, 175°C;N 2 flow rate, 35 ml/min

-45-

,,

!'

Table 6
Comparison of EC/GC and spectrofluorimetry (SF) estimations of CA concentrations in rat adrenal glaQds
1'____

Method

NE

N

±

ug/g tissue - S.D.
DA
35

504 ± 66

11.0 t 2

Reference

EC/GC

4

173

EC/GC

7

190

SF

10

160

±

6

899

t 65

(102)

SF

10

254

t 16

951

t 50

(96)

4.6

*: GC conditions: 5% GE XF-1105; column temperature, 175;
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,'

E

this dissertation

520

~

(95)

2 flow rate, 35 ml/min

in pyrogallol/ethanol rats.
(S.D.

± 11.5%)

Fig. 10 shows Porapak calibration curves

prepared for the estimation of blood AcD.

II. BLOOD ETHANOL AND ACETALDEHYDE LEVELS DURING PYROGALLOL/ACUTE ETHANOL
METABOLISX

In two separate experiments, blood AcD levels in pyrogallol pretreated, ethanol injected rats were estimated and compared to the levels
Fig. 11 shows the concentrations/

in rats treated with ethanol only.

time curves of AcD in these two ethanol groups.

20 min after i.p.

+

I

ethanol, the AcD blood level in "ethanol only" rats was 2.8 - 0.9 ug/ml.
In the pyrogallol/ethanol group the concentration of AcD at this time
was potentiated to 41
hours.

± 12 ug/ml blood and remained elevated after five

Thus, pyrogallol pretreatment elevates ethanol derived AcD ca.

10-15 fold, in agreement with other work in this laboratory (105).
Blood ethanol in both groups was determined 20 min after i.p.
ethanol and found to be elevated slightly but non-significantly in the
pyrogallol/ethanol group; 2.40 +

0.68 mg/ml compared to 1.95 +
- 0.52

mg/ml in "ethanol only" rats.
III. BLOOD ETPANOL AND ACETALDEHYDE LEVELS DURING CHRONIC ETH.c\?:OL
MEIABOLISi·1 (INTUBATION)

An estimate of blood ethanol and AcD in rats chronically intubated
with

ethanol

(the

alcoholic

rat

experiment)

was

obtained

on

the 15th and last day of intoxication, 2 hr before sacrifice (5-6 hr
after the last ethanol intubation at 0900 hr).
of 3.9 +
- 0.9 ug/ml and 1.6 +
- 0.75 mg/ml

The average values

for blood AcD and ethanol,

respectively, were obtained for six rats, agreeing with the results
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of Majchrowicz (77).

The results are compared with literature

values in Table 7.

F.

ACUTE ETHANOL METABOLISM
I.

FOLLOWING PYROGALLOL PRETREATMENT

a. EC/GC Analyses o.f Combined Brain Parts (brain stem, caudate
nucleus and midbrain, including hypothalamus)
Fig. 12, Chromatogram A, is a normal GC chromatogram ( on 3% OV17) of the combined brain parts from a control (pyrogallol/saline)
rat. The consistent appearance of a component (hatched peak) with a
retention time identical to salsolinol, the TIQ derived from DA and
AcD, was observed in the brain parts. of each pyrogallol/ethanoltreated rat (Chromatogram B), and was not observed in control samples.

This new component was clearly augmented when HFB-salsolinol

was added to the GC injection solution (Chromatogram C, Fig. 12).
The proof that this new compound did not result from reaction of
AcD during workup is supported by its absence from control brain
samples to which was added AcD (100 ug/ml) during homogenization.
Further more, the retention times of several catechol compounds
·which possibly could be present in the experimental brain and could
contribute to this peak agreeing with salsolinol were determined.
Table 8 shows that the HFB-derivatives of these compounds have
retention times quite different from salsolinol and the new component in the experimental brain parts.
To further verify the identity of salsolinol in the brain parts
of pyrogallol/ethanol animals, the experiment was repeated a fourth
time with nine rats.

Combined brain part extracts were derivatized
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Toble 7

Blood ethanol and AcD concentrationsl in the rat and human during chronic ethanol intoxication

Subject

Route of
ingestion

Amount/day
(g/ ~)

Duration of
Range
intoxication (day&\ Ethanol (mg/ml) AcD(ug/ml)

rat

gastr;ic
intu ation

8-12

15

120-350

2.7-5.1

rat

gastric
intubation

12-15

8

50-300

L0-3.0

(77)

human

free drinking

32 ounce of
50% grain
ethanol

100-400

1.0-2.5

(98)

'7-10

1. Determined by different GC methods
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I

I

Reference

this dissertation

LEGEND FOR FIGURE 12

EC/GC chromatogram of the HFB-catechol-containing
compounds in the combined brain parts of pyrogalloltreated rats following acute ethanol intoxication

·.

(chromatogram B) or saline (chromatogram A).
Chromatogram (c) shows the addition of 50 pg authentic HFB-salsolinol to the chromatogram (B) injection
solution.
GC conditions: 3% OV-17 on 80/100 Gas Chrom Q; coluum
temp.=160°c; N2 , 30 ml/min.

Att. 2 x 10-lO AFS,

except for DA in the control, which is 4 x io-10 AFS
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Table 8
Comparison of EC/GC retention times 1 of known catechol compounds to the unknown component detected in
CA-rich brain parts of pyrogallol/ethanol rats

Compound (HFB-derivative)

Retention time (min)

Unknown substance in experimental brains

6.45

Salsolinol

6.45

Epinine

3.50

N-acetyl-DA

2.75

3, 4-dihydroxy phenyl glycol

1.50

3, 4-dihydroxy phenyl ethanol

1.30

3-methoxy-catechol

1.30

Pyrogallol

1.00

l 3% OV-17;

column T, 160°C; Flow rate, 30 ml/min
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with PFP-anhydride in acetonetrile and were analyzed on SE-54.

A

component (shaded peak, Fig. 13) with a retention time identical to
PFP-salsolinol was observed in each experimental (pyrogallol/ethanol)
brain sample (h=5) but was not observed any of four control brain
parts.

Addition of authentic PFP-salsolinol to experimental sam-

ples increased the height of this new peak.
In Table 9 the effect of acute ethanol (7 hr metabolism) on the

CA concentrations and salsolinol formation in the combined brain
parts of rats treated with pyrogallol is shown.

The concentration

of salsolinol in the brain parts of all experimental rats averaged
from samples (three experiments) was 17 +
- 5.3 ng/g combined brain
parts.

As the data shows, DA and NE concentrations in the combined

brain parts of pyrogallol rats were depressed 45-55% and 30-40%,
respectively,by the ethanol treatment.
Interestingly, the presence of a substance identical to E in the
brains of all pyrogallol-treated animals was noted (Table 9) when
bra.in extracts were analyzed on 5% GE XF-1105 for CA quantitation.
Assuming this material is E, a higher concentration (83 +
- 20 ng/g
brain parts) was seen in the experimental rats than in the control
(66

t ng/g brain parts), but the increase was not statistically

significant.
Another interesting finding was the fact that an unidentified
component with an unusually long retention time (LRT) on GE XF-1105
of 60-70 min ("LRT"component), observed in all brain samples from
pyrogallol/saline controls, was nearly absent from all pyrogallol/
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EC/GC chromatogram of the PFP-catechol-containing co:T;icunds
in the combined brain parts of pyrogallol-tre2ted, acute
ethanol- injected i::ats. Hatched peak ide.ntical to auti-1.antic
PFP-salsolinol is absent from brain parts of saline co~trol
rats.

GC condition : 5% SE-54 on 80/100 Gas Chrom Q; Column Te:"'.lp .=: 160°c,
N2 - 30 ml/min, Att.= 2 x io-lOAFs
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Table 9
Effect of acute ethanol on salsolinol formation and CA concentrationsl in combined brain parts 2 of
pyrogallol-pretreated rats

Experiment
No.

+

Drug Treatment

3

DA

NE

ug[g tissue - S.D.
E

+
+

1

Pyrogallol/saline (4)
Pyrogallol/ethanol (5)

1.92 +
- 0.21
0.87 t 0.39">'•

0.80
0.09
0.63 - 0.20

2

Pyrogallol/saline (6)
Pyrogallol/ethanol (6)

1. 98 +
- 0 .17
i.os t 0.15·::

0.98 +
- 0.16
0.63 t 0.07

3

Pyrogallol/saline (5)
Pyrogallol/ethanol (7)

2.06 +
- 0.26
1.06 t 0.10•'(

1.02 +
- 0.15
0.60 t 0.07*

+

0.06 + 0.01
0.07 - 0.01

--

--

--

--

0.06 +
- 0.01
0.08 t 0.02

Salsolinol
not de_fectable
0.018 - 0 •.009
not detectable
0.017 t 0.004
not detectable
0.015 t 0.003

1. Values are corrected for recoveries based on 14 c-DA recovery (range: Exp. 1, 42.3% - 50.1%; Exp.2,
39.8% - 47.5%; Exp. 3, 40.9% - 53.0%)
2. Combined brain stem, caudate nucleus and midbrain including hypothalamus
3. Number of rats/group in parenthesis

*

p

<

0.01 compared to the pyrogallol/saline control
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ethanol brain samples.

Although k could not be quantitated, this LRT

component in the controls was a significant component

iri the HFB-

derivatized extracts, as judged by the area of its peak (70% deflection)
at 8 xlO -10 AFS.
b. EC/GC Analysis of Adrenal Glands
EC/GC qualitative results of adrenal glands of rats treated with
pyrogallol/ethanol, obtained on 5% GE-XF-1105, are presented in Fig.14.

A new (shaded) peak on the chromatograms, with a retention time identical to the major E-derived TIQ,gigantinol, was observed in all
adrenal glands from 18 experimental rats (pyrogallol/ethanol) but not
in adrenals from control (pyrogallol/saline) rats.

This peak was

potentiated when the HFB-d.erivative of gigantinol from E/AcH reaction
mixtures was added to the injection solutions.

The average estimated

concentration of biosynthesized gigantinol in 13 paiisof adrenal
glands (three experiments) was 3.7: 0.49 ug/g tissue, corresponding
to ca. 1-2% of the E levels in the experirn.ental animals.
E levels in adrenal glands underwent significant changes due to
pyrogallol/ethanol, as they decreased by 50-60% (Table 10).

A non-

significant 10/~ decrease, but nevertheless a definite trend, was also
observed in NE.

Conversely, DA levels were slightly increased, but

this change was not significant.
II.

FOLLOWING PARGYLINE-PYROGi\LLOL PRETREATMENT

a. EC/GC Analysis of Combined Brain Parts
The combined brain parts of rats treated with two doses of
pargyline, 24 hr and 1 hr prior to the acute pyrogallol/ethanol or
pyrogallol/saline administration, were analyzed for HFB-salsolinol
-57-
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Fig. 14. EC/GC chromatogram of the HFB-catechol containing compounds in
the adrenals of pyrogallol-treated, acute ethanol-intoxicated
rats. Hatched peak identical to authentic HI'B-gigantir,ol is
absent from adrenals of saline control rats.
GC conditions: 5% GE XF-1105 on 80/100 Gas Chrom Q; column temp.=175°c;
N2, 35 ml/min; Att. = 2 x lo- 10 AFS
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Table 10
Effect of acute ethanol on gigantinol formation and CA concentrations 1 in adrenal glands of pyrogallo~
pretreated rats

Experiment

2

No.

Dr1.1g _Tr~at_mer1t3___

ug/g tissue - S.D.
NE
E

-~------DA____

1

Pyrogallol/saline(4)
Pyrogallol/ethanol(5)

14.4 t 4.0
14.0 +
- 4.9

190
119

!:
t

2

Control (5)
Experiment (7)

10. 3 +
- 1. 7
15.2 t 2.1*

146
125

t 18

3

Control (6)
Experiment (6)

9.7 - 2.0
12.5 t 3.2

+

168
138

58
48

G_igantino14

560 t 18
301 ± 62*

not detectable
3.7 t 0.66

± 22

425
17'1

+- 46
+- 37*

not deiectable
4.0 - 1.05

± 35

434 ! 41
224 t 39*

not detectable
3.1 +
- 0.77

± 19

1. The values are corrected for recoveries based on 14c-E recovery (rarige, Exp.l, 59.8% - 75.2%;
Exp. 2, 61,0% - 69.7%; Exp. 3, 64.7% - 74.4%)
2. The CA concentrations in exp. 3 were calculated for per g protein in addition to per g tissue
shown and the results in both cases were similar (see appendix II)

a~

3. Number of rats/group in parenthesis
4. This figure at bc,st i>lwuld be considered a minimum estimate, because the aqueous E-AcD condensation itself forms 30-40% of supposedly other giganti.nol isomers (1) (which were not separable in
GC of adrenals), and because the calibration curve used for estimation was actually based on
quantity of stnrting amine (E) rather than on major product (gigantinol)

*

p <o.Ol colllpared to the pyrogallol/saline control
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on 3% OV-17.

The chromatograms were very similar to those from the

pyrogallol/ethanol experiments.

A component corresponding to salsol-

inol was observed (Table 11) in all pargyline-pretreated, pyrogallol/
ethanol rats, in significantly higher concentrations than in the
pyrogallol/ethanol brain samples (Fig.15).

The component was absent

in the brain parts of three out of the seven rats treated with
pargyline/pyrogallol/saline (controls) but, interestingly, the
remaining four controls demonstrated an extremely small quantity
(2~5

ng/g brain parts) of a component with a retention time identical

'•

to that of salsolinol.
Again the large peak area due to the LRT component was present
in the control brain samples and was significantly diminished in or
absent from the experimental brain parts.
quantify

No effort was made to

the LRT component and compare its area to other experiments.

As shown previously in Results, EC/GC is much less responsive
to the DA-derived benzyl-TIQ
able to expect the

for~ation

than to salsolinol.

But it is reason -

of the benzyl-TIQ in this experiment

because MAO inhibition has been known to increase both DA and THP
biosynthesis in vitro (10).

However, when pargyline/pyrogallol/

ethanol brain parts were examined on 3% OV-17 at 190°c, conditiorn at
which HFB-THP chro:natographs at 8.55 min, there was no evidence in any
experimental samples for THP.
Brain CA concentrations were estimated on 5% GE XF-1105.

Table

11 shows the expected increase in DA and NE levels in the combined .
brain parts of the control pargyline/pyrogallol/saline rats (by 130%
and

57% respectively) compared to the pyrogallol/saline control rats

-60-.

Table 11
The effect of acute ethanol on salsolinol formation and the CA concentrations
parts 2 of pargyline/pyrogallol~treated rats
~ug/ g

Drug Treatment3
Pargyline/Pyrogallol/

4.44

±

tissue-!" . s. D.
NE

DA

+

E<+

1.26 +
- 0.20

0.42

1 in the combined brain

Salsolinol
not detectable

Saline (4)

Pargyline/Pyrogallol/

3.27 t o.2s~b'(

0.68

~ 0.14*

o.11a

!"

0.020

Ethanol (7)
1 /.

1. The values are corrected for recoveries based on ....~C-DA recovery (range, 40.8'7'~ - 49.670).

-

2. Combined brain stem, caudate nucleus and midbrain, including hypothalamus.
3. Number of determinations
4. The values include both NE and E because 3'/o OV-17 column does not separate these two HFB-amines.

*

p

<9.01

,·d~ p ~.001
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in other experiments.

Acute ethanol administration in pargyline/

pyrogallol-treated rats again led to significant depletion of CAs
from the brain.
b. EC/GC Analysis of Adrenal Glands
EC/GC analysis of the adrenal glands of rats treated with
pargyline followed by pyrogallol/ethanol administration showed the
formation of the new catechol compound, gigantinol .. The concentration of this TIQ in adrenal glands of these experimental anirna1s
(Table 12) was not significantly higher that its concentration in the
pyrogallol/ethanol adrenals (Table 10).

Pargyline administration also

did not lead to a significant change in the CA concentrations in the
adrenal gland (Table 12 vs. Table 10).

Unlike brain (Table 11) acute

ethanol metabolism did not deplete the adrenal CAs in pargyline/
pyrogallol rats (Table 12).
III. FOLLOWH7G DOPA/ PYROGALLOL PRET"8.EA.r.1ENT

a. EC/GC Analysis of Combined Brain Parts
The quantitative determination of CAs in brain parts w2s performedon 5% GE XF-1105 and the results are shown in Table 13.

Agreeing with

earlier pyrogallol experiment {/:l and ://:2, Table 9, ethanol decreased
brain DA and NE very significantly.

However, DOPA administration to

the pyrogallol-treated animals before and during ethanol metabolism
did not prevent the depleting effect of ethanol.
Using 3% OV-17 column, salsolinol was observed in the brain parts
pf rats treated with DOPA/pyrogallol/ethanol (Table 13).

The level

of endogenously formed salsolinol was estimated to be 193% of the
amount formed in the brain parts of pyrogallol/ethanol treated rats,
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'Table 12
The effect of acute ethanol on gigantinol formation and the CA concentrations 1 in the adrenal glands
of pargyline/pyrogallol-treated rats

Drug Treatment 2
Pargyline-pyrogallol/
saline (4)

Pargyline-pyrogallol/
ethanol (7)

DA

ug/g tissue t S.D.
E

---~_L_______

11.7 t 3.0

172 t 16

13.7 +
- 3.5

164

t 5.5

390 t 95

327

t 55

3
Gigantinol
not detectable

4.0 +
- 1.0

1. The values are corrected for recoveries based on 14 c-E recovery (range, 66.5% - 74.0%)
2. Number of rats/group in parenthesis
3. This figure <::t best should be considered a minimum estimate, because the aqueous E-AcH condensation
itself forms 30-4.0/'., of supposedly other gigantinol isomers (1) (which were not separable in GC of
adrenals), anJ because tlte calibration cunre used for estimation was actually based on quantity of
starting ami1w (E) rather than cn ni:1jor pcocluct (gigantinol).
1
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Table 13
The effect of acute ethanol or DOPA/ethanol on salsolinol formation and the CA concentrationsl in
combined brGin parts 2 of pyrogallol•treated rats.

' tissue +- S.D.
ug/g
E

Drug Treatment 3

Salsolinol

DA

NE

Pyrogallol/saline (5)

2.06 t 0.26

1. 02 +
- 0 .15

0.06 +
- 0.01

not detectable

Pyrogallol/ethunol (7)

1.06 +
- 0.10'""

0.61 +
- 0.07*

+
0.08 - 0.02

0.015 :t 0.003

DOPA/Pyrogallol/ethanol(6)

+
1.10 - 0.26*

0.59

t

1. The values are corrected for recoveries based on

0.08*

14

0.0'8

t

0.01

C-DA recovery (range

2. Combined brain stem, caudate nucleus and midbrain including hypothalamus.
3. Number of rats/group in parenthesis

*

p ~0.05 compared to pyrogallol/saline
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0.029

"!:

39.8%-47.7%)

0.015*

althoug this increase was not statistically significant.
b. EC/GC Analysis of Adrenal Glands
The level of E in the adrenal glands of pyrogallol treated rats
was decreased by ethanol similar to previous pyrogallol experiments
(table 12), but 1-DOPA given once before and once during ethanol
metabolism, did not prevent ethanol depleting effect on E.

Further,

it should be noted that DOPA/Ethanol treatment significantly lowers both
adrenal NE and DA in pyrogallol rats.
Administration of 1-DOPA did not have a significant effect on the
concentration of the biosynthesized E-derived TIQ (gigantinol) in the
adrenal glands of pyrogallol/ethanol treated rats (Table 14).
IV. FOLLOWING RESERPINE/PYROGALLOL PRETREATMENT
Rats treated with reserpine (2.5 mg/Kg i.p.) could not tolerate
the following day's acute pyrogallol/ethanol treatment.
experimental rats died within
injection.

15~45

All seven

minutes after the first ethanol

The intention of this experinent was to deplete the tissue

CAs and to observe the effect on TIQ biosynthesis.

The experiment was

not repeated with a lower dose of reserpine althoug such a change
might be adequate to ensure survival.
V. IN THE ABSENCE OF DRUS TREATIIENT

a. EC/GC analysis of whole brain
The qualitative EC/GC analysis of the brains of acute (7 hr)
ethanol-treated rats with no drug pre-treatment was performed on 3%
OV-17 (chromatogram is not shown).

In the ethanol animals there was

no detectable evidence for salsolinol biosynthesis in whole brain; CA-
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Table 14
The effect of acute ethanol or DOPA/ethanol on gigantinol formation and the CA concentrations 1 in the
adrenal glands of pyrogallol-treated rats

Drug Treatment

2
DA

ug/g tissue
E

NE

+

Pyrogallol/saline(4)

14.4 - 4.0

190

± 58

Pyrogallol/ethanol(S)

14.0

t

4.9

119

-:!:"

48

301

t

8.0

:t"

3.4"0 '<-

100

:t

23*

216

± 64•'<'

DOPA/Pyrogallol/ethanol(6)

560 t, 18
62•'<'

± S.D.

Gigantino1 3
not detectable
3.7

± 0.7

3.3 +
- 1.0

1. The values are corrected for recoveries based on 14c-E recovery (range, 57.4%- 71.7%)
2. Number of rats/group in parenthesis
3. This figure at best should be considered a minimum estimate, because the aqueous E-AcH condensation
itself froms 30-4.0% of supppscdly other gigantinol isomers (1) (which were not separable in GC of

adrenals), and because the calibration curve used for estimation was actually based on quantity of
starting amine (E) rather than ofmajor product (gigantinol)
<'(

*''(

p <0.01 compared to pyrogallol/saUnc.
p <0.05
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rich brain parts were not examined separately in these

~eriments.

Again, similar to the preceding experiments with pyrogallol/
saline and combined brain parts (vide supra), the whole rat brains
from controls (saline only) showed the presence of significant
quantities of the unknown LRT component.

The acute ethanol treatment

resulted in the almost complete disappearance of the

L~T

component

from the whole brain, analogous to the pyrogallol/ethanol experiments.
The quantitative effect of ethanol on CA concentration of brain,
evaluated on 5% GE XF-1105, is in table 15.

A

sw~ll

and non-significant

decrease of CAs was observed in the whole brain of ethanol-treated
rats compared to saline controls.

G. CHRONIC ETHANOL METABOLISM IN THE ABSENCE OF DRUGS
I. GASTRIC INTUBATION TECHNIQUE
In this experiment, rats were intubated two and later three ti::res
daily for 15 days with 25% ethanol in water (v/v) or
water (w/v) (Experimental, vide supra).

21~~

dextrose in

Throughout the e::tire study

the experimental animals were sluggish but did not shew any other
gross behavioral changes.

The first day the food

inta~e

for

experimen ta.ls dropped more than 90% of the pre-ethanol fo-od levels,
but then it gradually increased and stabilized at about 25% of this
pre-ethanol level after five days.

The pair-fed control. :.·ats shc'.:e.d

hunger-related anxiety for the daily pellet ration,

~;hi ch

had been

determined from the experimental rat pellet consumption of the
preceding day.

Water intake ad lib

between controls and experimentals.
intake

(experimental=controls)

did not differ significantly
In Fig. 16 are plotted food

and body weight changes vs. tir:::e.

-68-

"Table 15
The effect of acute ethanol on the DA and NE concentrations 1

.
+- S.D.
ug I g tissue

.
2
E xperi.ment

DA

Saline (control)

in the whole brain of rats

(4)

Ethanol (5)

NE

+

0.74 +
- 0.15

0.38 - 0.07

0.61 +
- 0.19·

0.33 +
- 0.07

1. The values are corrected based on the average recovery of 14c-DA in these studies
2. Number of rats/group in parenthesis.
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a. EC/GC Analysis of Brain and

Adren~l

CAs

Fig. 17 shows the superimposed chromatogram of control (solid
Evaluation of

peaks) and experimental brain parts (dashed peaks).
experimental brain parts showed no evidence for the
derived salsolinol during chronic intoxication.

occure..~ce

of DA-

However, similar to

the saline controls in acute ethanol experiments, the brain parts of
these control rats (pair-fed, isocaloric dextrose -treated) showed
the presence of theLRT component (peak at 62 min) in large quantities.
It was nearly absent from the brain parts of chronic ethanol rats
(dashed line at 62 min).
In terms of potential TIQ biosynthe.sis, there was no EC/GC
evidence on 5% GE XF-1105 for any new catechol compounds in the
experimental adrenals.

The superimposed chromatogram in Fig.18

shows the quantitative changes in adrenals between cont:-ols (solid
peaks) and experimentals (dashed peaks).
The quantitative analyses of brain parts and adreLal glands are
summarized in Table 16.
DA in the combined brain parts was decreased
ethanol and was unchanged in the adrenals.

24~~

by chronic

NE was lowered

.6.3~s

brain parts, and 54% in the adrenals, by the chronic ethanol

in

~etabolism.

E was depleted 42% in the adrenals by ethanol.
b. EC/GC Estimation of 0-methylated CA Derivatives in Brain
HFB-derivatives of the O-methylated CA metabolites extracted
from the combined brain parts of each chronic ethanol and control rat
were determined on 5% GE XF-1105.

a 130%

The results (Table 17) demonstrate

increase in the level of the DA metabolite, 3-nethoxy-tyramine,

.

in the combined brain parts of alcoholic rats compared to controls.
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Table 16
The effect of chronic ethanol on the CA concentrations in the combined brain parts
glands of rats

ug/g brain 2

CA

control

( fj.

DA

0.93 t 0.10

NE

0.53 - 0.08

y';

+

chronic ethanol (7)

+ O.OS-io'<-

-

+
0.30 - 0 .02'"/d:

E

1. Combined brain stem, caudate nucleus

and adrenal

3 +
ugLg adrenals - S.D.
control(4)
chronic ethanol(7)

± S.D.

0.68

1

21.3 +

3.0

17.8 +

192

+ 45

89

550

+ 91

344

+
-

3.6
16**

+ 36**

-

and midbrain,including hypothalamus.

2. The values are corrected based on the average recovery of 14c-DA in earlier experiments

3. The values are corrected for recoveries based on 14 c-E recovery (range 65.3%-70.6%)
'"/c

Number of rats/ group

*"c p

<

0.01 compared to control
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Table 17
Tl1e effect of chronic ethanol on 3-rnethoxy-tyramine and nonnetanephrine concentrations in the combined
brain partsl of rats.

Drug Treatrnent 2

ug/g tissue + S.D.
normetanephrine
3-rnethoxy-tyrarnine

Dextrose solution (4)

244 t 34.4

Ethanol solution (7)

560 + 75.0*

1
2

126 + 8,6

Combined brain stern, caudate nucleus and midbrain including hypothalamus
Number or rats/group in parenthesis

,'<: P<0.01
*,'<: p<0.05

compared to dextrose control
compared to dextrose control
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The increase

in

NE metabolite, nortnetanephrine, was smaller (24%)

but was still statistically significant.

II. CHRONIC i.p. INJECTION TECHNIQUE
As stated in Experimental, this experiment was terminated due to
animal deaths.

After the first day the food intake of experimental

rats diminished to less than 10% of their pre-ethanol levels and there
was a corresponding rapid weight loss.

After four days the.experimental

rats developed severe diarrhea and most died within the next several
days.
H. ACUTE

No amine analyses were carried out.

METHfu"!OL METABOLISM

I. FOLLOWING PYROGALLOL PRETREATMENT

In this experiment rats were treated with pyrogallol one h::mr
before the acute methanol administration described in t:1e 2:<'.'-'e::-::..:-:-,ental
section.

The blood levels of methanol and HCHO were not

in

~easured

these eh'Perimental animals.
The EC/GC results from the qualitative analyses of brain parts
on 5% GE XF-1105 demonstrated no detectable appearar:.ce of CA/:tC::O
derived TIQs; therefore the chromatograms are not

sho~.;n.

Howe-:er,

the LRT component was obvious in the brain parts of ooth control
(pyrogallol/saline) and experimental

(pyrogallol/~.et!-_a::2l:

r=~ts;

:'. .e.

the methanol administration did not lead to any apparent decrease in
the unknown LRT component in the brain.
Quantitative analyses of CAs in the brain gave different results
from those analyses of acute ethanol metabolism experinents.

The

concentrations of DA and NE in the combined brain parts fro~ pyrogallol/
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methanol rats, slightly higher than the control, were not statistically
different (Table 18); the slight increase in brain E was statistically
significant.
Fig. 19 is an EC/GC chromatogram of adrenals.

It shows the pres-

ence of a new catechol component (hereafter, for discussion purposes,
referred to as 1-nor gigantinol) appearing in all pyrogallol-methanol
rats but not in any of the controls, which could be potentiated by the
addition of the HFB-derivative of the major E/HCHO-derived TIQ to the

GC injection solution.

A second unidentified component was also seen

in 3 of the 5 experimental adrenal glands.

Its retention time was in

vicinity of CA-derived TIQs, but did not correspond with any of the
available compounds.
Table 19 shows the effect of methanol on CA concentrations in the
adrenal glands of rats treated with pyrogallol.

Large and statistically

significant depletions in adrenal E and NE (86% and 75%, respectively)
occurred due to the methanol metabolism in pyrogallol-treated rats.
II. IN THE

ABSE~ICE

OF DRUG TREA.TMENT

As is apparent in the chromatogram, Fig. 20, acute methanol
administration to the rats without prior drug treatment resulted in
the fonnation of two new catechol compounds in adrenal glands.

The

first new peak corresponded to 1-nor-gigantinol, the cyclization
product of E and HCHO.

The height of this first new peak in the

experimentals was increased when the HEB-derivative of E/HCHO
cyclization products were added to the injection solution.

The

concentration of suspected 1-nor-gigantinol, when peak areas were
compared, was 20-30% less than in adrenals of pyrogallol/methanol
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'l'able 18
The effect of acute methanol. on the CA concent:··ationsl in the combined brain parts2 of pyrogallol'
treated rats

Drug treatment

3

ug/g tissue

E

0.80 +- 0.09

0.066 t 0.008

DA
Pyrogallol/saline (4)

1.92 +- 0.21

Pyrogallol/methanol (5)

2.10 - 0.24

+

+ S.D.

NE

1.02

± 0.18'f(

0.094 t 0.010*

1. The values are corrected for recoveries based on 14c-DA recovery (range, 41.3% - 49.9%).
2. Combined brain stem, caudate nucleus and midbrain,including hypothalamus.
3. Number of rats/group in parenthesis
.,._ p "<::: 0. 05 compare<l to pyroga llol/ nall.nc control
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Table 19
The effect of acute methanol on CA concentrations 1 in the adrenal glands of pyrogallol-treated ratsi

ug/g tissue +
- S.D.
NE

Drug treatment 3

DA

pyrogallol/saline (4)

pyrogallol/methanol (5)

10.4 +
- 2.0

8. 2

92.6 +
- 2.2

t 2. Oi(

22.7

t

3.2*

E

325

t

17.0

87 t

1. The values are corrected for recoveries based on 14c-E recovery (range, 61.1%-73.5%)
2. Rats weighed 550±~ in this experiment.
3. Number of rats/group in parenthesis.

*

p< 0.01
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rats (vide supra).
A second newly-formed component also absent from control
adrenals, was observed in all adrenal glands of experimental rats at
7.'JJ min on the chromatogram (Fig.zc)).

This unidentified component had

different retention time than the second unidentified component ( 14.0
min) in the adrenal glands of pyrogallol/methanol treated rats.
Although its retention time was in the range of simple TIQs, it did
not correspond to the TIQ substrates available for this study.
In whole brain the qualitative results of acute methanol
metabolism were approximately the same as in pyrogallol/acute
methanol metabolism; that is, TIQ formation was not seen in the
whole brain of methanol-treated rats.

The LRT component was present

in all brains and did not appear to be depleted by methanol
metabolism.
The quantitative effects of methanol on CA concentrations in
whole brain and adrenal glands of rats are in Table 20 and 21.
respectivelyo

Similar to its effect in the pyrogallol experiment,

methanol did not alter the brain CA concentrations after seven hours
metabolism, but it significantly decreased adrenal E(by 68%), adrenal
NE (by 74%) and adrenal DA (by 55%).

-82-

Tnble 20
The effect of acute methanol on DA and NE concentrations 1 in the whole brain of rats

Drug treatment 3

t!g/ g tissue "±' S. D.

____ _

DA

NE

Saline (5)

0.55 +
- 0.01

0.13 +
- 0.01

Methanol (5)

0.48 +- 0.07

0.12 +
- 0.01

1. The values are corrected for recoveries based on

14

2. Number of rats/group in parenthesis.
3. Number of rats/group in parenthesis
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c-DA recovery (range, 34.4%-48.2%)

PART FOUR
DISCUSSION AND CONCLUSIONS

A.

TIQ BIOSYNTHESIS DURING ETHANOL METABOLISM
In three sequential experiments, each GC chromatogram (Fig.12 B)
obtained from the combined brain parts of rats treated with pyrogallol
followed by ethanol demonstrated a new component not observable in
the pyrogallol/saline controls (Fig. 12 A) that had a retention time
identical to salsolinol, the TIQ cyclization product of DA and AcD.

HO
HO

SALSOLINOL

The amount of this component was augmented when the HFB-derivative
of authentic salsolinol was added to the injection solution (Fig.12 C).
The possibility exists that the suspected salsolinol
workup was eliminated by control

homogeniza~ion

for~d

in the

with added AcD.

Other

catechol compounds such as N-acetyl-DA, epinine, dihydroxy-phenylethanol, dihydroxyphenylglycol, as well as pyrogallol and its metabolites (3-methoxy-catechol and 2,3-dimethoxyphenol), all had retention times different from salsolinol and the new brain canpound.
When brain DA was significantly elevated by pargyline administration

to

the animal

prior

to pyrogallol/ethanol treatment, the
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'··

concentration of salsolinol in brain parts also was potentiated
above the level observed in non-pargyline, pyrogallol/ethanol rats.
Since precursor (DA) is increased ctue to MAO inhibitiort;''higher
levels of product (salsolinol in the high AcD environment occurred.
Using another derivatization method and column, salsolinol was
again observed in combined brain parts of pyrogallol/ethanol rats.
According to Wilk and Zimmerberg (99) and others (80, 106),
identification of an unknown compound by GC is established through
comparison of the retention times of two different derivatives of
that compound on two or more columns with those of "authentic" substrate.

Both of these techniques - varying the

der~vative

(HFB-and

PFP-) and the columns (GE XF-1105, SE-54 and OV-17), including
column temperatures - were done in order to positively identify
salsolinol.
In the brain of rats receiving ethanol (acute or chronic) there
was no sign of a new component which could be salsolinol.

This no

doubt was because of the 1/8 - 1/10 lower concentrations of AcD in
the blood (1-3 ug/ml) and tissues of these rats than those treated
with pyrogallol/ethanol.

Pyrogallol administration is 2rJparently

the important factor in producing EC-detectable

a1~-0unts

of salsolinol

in the tissues of ethanol-treated aniinals. Concerning pyro;o: llo 1' s
effect on AcD levels, it is likely that this comes about via inhibHion of aldehyde oxidation pathways (105).

Thus this drug paten-

tiated the level of endogenously-formed catechol TIQ alkaloids not
only by inhibiting the CO}IT catabolism (51, 52), but also by elevating the reactant, AcD (and possibly the CAs).
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Nevertheless, these findings as well as the recent demonstration
by Sandler et al (49) ought to be encouraging to investigators in the
field of neurochemistry of alcoholism.

However, the latter study

only demonstrates the presence of TIQs in urine without proving that
this formation was in blood or tissue.

Since DA is a normal constituent

of urine (100,101) and AcD is probably present in urine after ingestion
of ethanol, it is probable that such a cyclization would take place in
the urinary tract.
Unexpectedly, 1-DOPA injection before and during ethanol metab-

·.

olism in pyrogallol-treated rats did not raise brain DA concentrations.
Compared to pyrogallol/ethanol rats, only a slight but significant
increase in salsolinol was observed.

It has been shown that 1-DOPA raises

brain DA in ethanol-intoxicated rats (109).

One partial explanation is

that condensation of 1-DOPA with AcD, present in abnormally high levels,
forms another TIQ (3-carboxy-TIQ) and diverts 1-DOPA from its DA
precursor role.

The ease of this DOPA/AcD cyclization has been described

by Brossi et al (43).

CH

3

Tet~ahydropapaveroline

l-methyl-3-carboxy
6,7-dihydroxy-TIQ
(3-carboxy-TIQ)
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(THP)

The. postulation of in vivo aldehyde condensation with DOPA is
not without precedent.

Pfeiffer and Ebadi (118) have suggested that

a similar cyclization between DOPA artlpyridoxal phosphate takes
place and leads to an inhibition of the DOPA-induced elevation of rat
brain DA when the two compounds are administered together.

However,

this amino acid/AcH cyclization would have to be quantitatively
significant in order to nullify the DA-elevating effect of DOPA.
Alternatively, the 3-carboxy-TIQ itself may have inhibiting effects on
DA biosynthesis or storage.

According to Cohen (103),3-carboxy-TIQs

are not decarboxylated substantially by DOPA decarboxylase.

This

would explain the relative lack of change in the salsolinol concentrations, if DOPA/AcD condensation had occurred.
THP, a more complex DA-derived TIQ alkaloid (above),is reported
to be found in rat brain homogenate incubated with DA and ethanol or
AcD (104), and in the urine of Parkinsonian patients (49).

THP was

not detected in the brain parts of pargyline/pyrogallol/ethanol rats.
However, the very low EC sensitivity of HFB-THP (:,IDQ=2JOpg) would
require that 100-200 fold more THP than salsolinol be biosynthesized
in brain.

Thus THP tissue biosynthesis could have occurred to a much

greater extent than salsolinol biosynthesis in these experiments and
still would be undetectable by the EC/GC method.

Mass fragr:entography

would be more helpful than EC/GC for the detection of HFB-THP.

The

relatively high concentration of peripheral DA in Parkinsonian patients
treated with 1-DOPA no doubt was significant in facilitating the
formation of THP in urine or tissue (49).
NE/AcD•derived TIQ was not observed in brain of experimental
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rats either.

Several reasons may account for this.

Fig. 8a shows

clearly that the EC detector response to this TIQ is about 10-15 times
less than to salsolinol.

Furthermore, the velocity of reaction

between NE and AcD is about 1/8th that of the DA and AcD reaction.
.
.
Robbins (47) found the second order
rate constant ( l:J..ter
mol -1 min -1 )

for alkaloid formation (pH 7.4 at 37°c) between AcH and DA, 1-DOPA or
NE to be 15.3, 6.1 or 1.9 respectively.

Finally brain NE concentration

is over 50% less than DA.
As stated previously, ethanol metabolism in the "chronic alcoholic"
rat did not result in detectable amounts of brain salsolinol. However,
one major and possibly important difference was obvious between the GC
chromatograms of control rat brain tissues and the chromatograms of
brain tissue from chronic alcoholic as well as acute alcohol-treated
rats (Fig.17 ).

This was the existence of relatively large amounts of

long retention time (LRT) component

only

in the controls.

The

identity of this component which is so rapidly depleted by ethanol
ramains undetermined, since this study was concerned primarily with
TIQ biosynthesis.

As a suggestion, the LRT component may be a volatile

derivative of cofactor, NAD, which is depleted during ethanol metabolism.

Consistent with this is the result that methanol, which is

thought to be metabolized in the rat via hepatic catalase (107), did
not lead to the disappearante of this unknown peak.

However, the low

activity of NAD-dependent aldehyde dehydrogenase in brain, as reported
by Raskin and Sokoloff (108), does not support this suggestion.
Polyhydroxy steroids, when derivatized with HFB-groups, may have
long retention times.

The LRT component may be such a normal brain

steroid which is depleted by ethanol or its metabolites or by some process
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activated by ethanol, such as CNS transport (141).

No EC/GC comparisons

were done of retention times of HFB-derivatized NAD or any other normal
brain material to the LRT component in nonnal rat brain.
TIQ biosynthesis in adrenal glands of pyrogallol/ethanol rats was
also observed.

The experimental animals demonstrated the presence of

a new adrenal catechol derivative which was absent in pyrogallol/saline
controls.

This component could be augmented by the addition to the

injection solution of the HFB-derivative of gigantinol (l,2-drmethyl4,6, 7-trihydroxy-TIQ).
'•

OH

GIGANTINOL

Pargyline pretreatment did not affect the quantity of biosynthesized
gigantinol in the a:lrenal glands.

Tne reason that this drug acted

differently between brain and adrenal gland is not clear but may involve
the possible specific effects of pargyline on different HAO isoenzymes
(110,111,112,113).

Selective inhibition of ~!AO action on different

substrates las been reported by several investigators (112,114).

Zeller

(115) noted the differences in potency of pargyline as an MAO inhibitor,
depending on which substituted benzylamine was used as a substrate.
Squires (116), studying the selective action of various inhibitors on
MAO in different organs of animals, suggested the presence of two ~·!AO
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fra~tions,

A and B, in varying ratios in different tissues.

shown that pargyline selectively
MAO in most species.

in~ibits

It was

the B fraction (116) of

To our knowledge no investigation has been

carried out on the types of MAO in the adrenal glands. It is possible
that A/B ratio of MAO is tmJch larger in adrenal glands than brain,
therefore making MAO les sensitive to pargyline inhibition. Nevertheless, 90% inhibition of MAO enzyme apparently is required (117)
to fully observe elevation in CA levels.

These findings may

describe in part why changes were not observed in adrenal CAs and
gigantinol due to pargyline administration, while significant increases were observed in brain DA and salsolinol concentrations.
The effect of 1-DOPA on the level of E and gigantinol in adrenals of pyrogallol/ethanol rats was insignificant. As mentioned
above in Discussion, it is possible that the normal metabolic pathway
of DOPA-DA in the presence of high AcD concentration is diverted to
the formation of 3-carboxy-TIQ.

This TIQ might be exerting an inhib-

itory effect on CA metabolism at the decarboxylase stt:?, or interfering with CA storage in chromaffin cells.
B. TIQ BIOSYNTHESIS DURING HETHA2WL HETABOLISM

Acute alcohol intoxication experiments also were carried out with
methanol. The metabolite,formaldehyde (HCHO) condenses with C.\.s in
vitro 25-50 times faster than AcD (1), and therefore TlQ iorT'l2.tion
might be expected. Administration of methanol to untreated or
pyrogallol-treated rats resulted in a new adrenal product with an EC
/GC retention time agreeing with 1-norgigantinol (the simple TIQ
derivative of E and HCHO). TLC evidence for adrenal norgigantinol and
.the NE/HCHO-derived TIQ has been reported(45).In these present exper-91-

iments there was no indication of the NE/HCHO derived alkaloid in
adrenals.
Pyrogallol administration did not increase the concentration of
suspected 1-norgigantinol in the adrenals. The level of blood HCHO
in rats after treatment with methanol or pyrogallol/methanol was not
determined.

Apparently pyrogallol does not inhibit the catalase

system (105) which is responsible for methanol metabolism in

rat(l07~

Therefore, HCHO level, unlike AcD, would not be expected to be
increased by pyrogallol, and detectable TIQ concentrations would
depend only on the COMT inhibitory effect of pyrogallol.
A scond new compound in the range of TIQ and CA retention times
with a peak area about 25% less than that of 1-norgigantinol consistently wa.s seen in the

chromatograms of the adrenals from rats treat-

ed with methanol only (Fig. 20, page 81). The possibility exists that
this was another oxidized catechol metabolite of 1-norgigantinol or
the TIQ derived from

~:E,

but due to the lack of authentic substrates,

this idea could not be checked out.

However, it is perhaps signif-

icant that pyrogallol pretreatment caused this second unidentified
adrenal compound to disappear (or change) concomitant with the

for~~

tion of another new "second" peak still within the range of TIQs and
CAs at 14.0 min (Fig. 19, page 79).
It is possible that both new "second" peaks are E-derived TIQ
products from two different catabolic pathways, one significant and
the other normally insignificant. Pyrogallol may cause a,metabolic
shift towards the nonnally insignificant pathway. I t is also possible
that pyrogallol somehow affect the E/HCHO cyclization reaction leading to a different isomeric product.
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An alternative explanation is that the new "second" adrenal
peaks in methanol and pyrogallol/methanol rats are CA rather than
TIQ metabolites, 3-methoxy-4-0H-phenylglycol (MHPG) and dihydroxyphenylglycol (DHPG), respectively.

MHPG, considered to be the major

catabolite of brain NE (134, 139), may be a minor catabolite in the
(control) adrenals.

Methanol metabolism, by increasing the reductive

capacity of adrenal tissue, might increase MHPG concentrations
sufficiently so that MHPG would be carried over or extracted by the
Al 0 procedure. Inhibition of C0}1T by pyrogallol would decrease
2 3
MHPG and increase its precursor, DHPG, perhaps to detectable concentrations.

Further work is necessary in order to identify these new

components in the adrenals of methanol-intoxicated rats.
It is puzzling that; contrary to the adrenal situation, there
was no GC evidence for TIQ biosynthesis from the condensation of
brain CAs with HCHO in the methanol-intoxicated rats (with or without
pyrogallol).

Due to the high reactivity of HCliO with DA (119) it is

possible that some kind of condensation reaction may have taken place
but metabolism of the TIQ (1-norsalsolinol) occurred during the 8 hr
experimental time.

Time studTes should be performed to follow up this

suggestion.
C.

CA. Concentrations in i\ormal Rat brain and Adrenal Glands

It is known tha HFB-derivatives of biogenic amines show larger
E.C. responses than their TFA-and PFP-analogues (83, 123). In addition,
because of longer retention times, HFB-derivatives sometimes demonstrate
better GC resolutions.

These aspects were used to separate HFB-TIQs

from the HFB-CAs in pg amounts.

Although the% recovery was lower
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than the Arnold and Ford method (83), the reproducibility for
catechol compounds and their metabolites was excellent.

The applica-·

tion of 14 c-tracers was used to determine total losses from tissue
during the purification steps and corrections for this loss served
for the precision of results.

The precision obtained from repeat

estimations of CAs in the brain parts of pyrogallol-treated rats
(Table 22), demonstrates the reliability of th.is EC/GC technique in
tissue analyses.
This technique was used successfully for the analysis of less
than 10 mg of brain tissue and for the recovery of as little as 10 ng
of added 4,6,7-trihydroxy-TIQ with tissue DA and NE.

DA, NE and E

concentrations were also estimated in the whole brains of individual
rats and the results (Table 5, p 45) compared favorably with the
spectrofluorometric analyses of Shellenberger and Gordon (97) and
Barchas et al (96).
In this EC/GC technique, the small difference obserbed between
the values of brain NE on two different columns (Table 5, p 45) could
be due to the lack of separation of NE from E on SE-54 (or OV-17) as
opposed to GE XF-1105.
The concentrations of CAs in adrenal glands of normal rats were
found with HFB-derivatives on GE XF-1105 to be in close agreement
with the_GC results reported by Imai et al (95).

Concentrations of

adrenal E measured by spectrofluorometric methods are higher than that
determined by GC methods (Table 6, p 46).

This diversity could be

due to the strain differences in experimental animals, or to interference of non-specific materials with the spectrofluorometric method.

-94-

Table 22
Comparison of the results obtained from repeat estimation of CAs in the combined brain parts of
pyrogallol-treated ratsl

ug/g tissue 2
ExEeriment No.

No. of rats

DA

NE

t S.D

+

E

1

4

1.92 +
- 0.21

0.80 - 0.09

0.063

2

6

1. 98 - 0 .17

+

0.99 +
- 0.11

0.080 - 0.016

3

5

2.06

!

0.26

1.02 +
- 0.15

0.058

4

5

2.02 +
- 0.50

1.05 - 0.31

t

0.009

+

! 0.010

+

1 control rats for acute ethanol metabolism experiments, Experimental, p.32

2 the values are calculated_ per g combined brain parts (brain stem, caudate nucleus and midbrain,
including hypotbalamus)
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"

The r:esults from pyragallal-treated rats indicate the existence
of E in the rat brain.
of controversy.

The presence of E in the CNS has been a matter

Since the suggestion was made by Von Euler (124) that

E (sympathin) exists in mammalian brain, many investigations have been
made on the problem.

The ratio of E to the sum of E and NE in rat

brain was reported to be 0.045 by Gunne (125) 0.034 by Montagu
determined by fluorocetric methods.

(126),

On the other band, Sano and

Taniguchi (127), using Amberlite IRC 50 for the separation o_f' CAs,
and the trihydroxyindole fluorometric method, found no E in the brain.
Carlsson (128) and McGeer and McGeer (129) also failed to detect this
amine by fluorometry.

Anton and Sayre (89) conjectured that the large

amount of DA in the brain may interfere with the fluorometric measurement of E.

Imai et al (95) with EC/GC and TFA derivatives, have

raeasured 150 ng E/ g of whole rat brain.

As shown in Table 9, p56

the average concentration of E in the combined brain parts of pyrogalloltreated rats was 66 -:!:: 8 ng/g tissue, which is about 6.6% of the NE + E
concentrations in the same brain sample.

The possibility exists that

circulating E in blood contributes to this "brain E" value.

However,

the small quantity of blood within the brain at decapitation with an
E concentration of 60 ng/L ( 102) could not contribute more than 50-100
pg E to the average value.
E was not estimated in brain samples from !l2!l-pyrogallol-treated
rats(contro~.

analysis

One reason for this was that in the whole rat brain

a relatively large unknown peak tended to overlap with the

retention time of HFB-E on GE XF-1105.

It was for this reason, in fact,

that organic solvent extraction (91), in case the interfering component
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was lipid,

"WaSi

att:elllp'ted; in one. experiment (Experimental, vide

supra), but with little success.

In combined brain parts this

component interfering with E, although diminished, was still apparent.

Pyrogallol pretreatment served to potentiate brain E (perhaps

due to inhibition of CO}!T catabolism) and permit its estimation in
saline controls.
D.

THE EFFECT OF ALCOHOL METABOLISM ON RAT BRAIN Ai.1' ADRENAL CA
CONCENTRATIONS
Conflicting data on the effect of ethanol on brain amine
concentrations has been reported (Introduction, vide supra). This
discrepancy has been attributed by some to ethanol-derived AcD, causing the release of CAs from the CNS(26,34). In this study, acute

I

I

ethanol metabolism in the absence of other drugs did not change brain
or adrenal CA concentrations, in agreement with Haggendal and
Lindquist(31) and others (30). However, sharp decreases in the
respective CAs to ca. 50% of control brain DA and NE and control
adrenal E concentrations were observed when the acutely intoxicated
rats were pretreated with pyrogallol. Because blood AcD levels during ethanol oxidation were elevated by pyrogallol, the decreases in
CAs probably reflect in part or in total the releasing action of
AcD on CA stores.
Chronic ethanol metabolism for 15 days(in the absence of other
drugs), however, which generates an "alcoholic" rat(77), did result
in significant 25-50% decreases in brain DA and NE and adrenal E.
Thus when control rats are properly handled, and paired nutritionally
.with experimental alcoholic rats, changes in CA due to "alcoholism"
become apparent.

The lack of adequate nutritional controls may

explain why some investigators reported no brain amine cbanges fol-
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,I
11'
,
'I

lowing chronic ethanol gavage in the rat (33).

Furthermore, the deple-

tion observed here may be due as much to the chronic presence of AcD
(estimated at 4 ug/ml at sacrifice) as to ethanol.
Alternately, the data from methanol metabOlism experiments indicate. that HCHO-derived TIQ may be involved in the CA depletion process.
In adrenals, which were shown to possibly contain

TIQ(s) derived from

E, significant depletion of E and NE was seen, whereas in the same rat,
no TIQs and no CA decreases were observed in the brain.
The mechanism by which HCHO-derived TIQs might lower CA concentr&tion is speculative.

Cohen has shown that DA/HCHO cyclization products

release and inhibit the uptake of CAs in vitro (55, 130). It is possible
that certain TIQs can displace CAs from storage and receptor sites.
Tabakoff et al (132) have reported that salsolinol and morphine easily
displace 5-!IT from its "binding site" in brain tissue. Perhaps TIQs act
on membrane as has been suggested for 6-hydroxy-DA (131) to increase
permeability to or block the uptake/storage of CAs. The striking structural similarity, shown in Fig.21, between a possible quinoid oxidation
product of DA/HCHO-derived TIQ and the hypothesized active quinone from
of the in vivo CA depletor, 6-hydroxy-DA (133) suggests a mechanism by
which the TIQ itself could lower CA levels.

Pharmacological wor:.C is

necessary with the synthetic TIQ.
As DA and NE in brain during chronic ethanol

consun~rtion

are

decreased by whatever mechanism, one expects an increase in 3-methoxytyramine and normetanephrine, metabolites produced by the action of
extracellular COMT on the amines.

In fact, this proved to be the case.

Brain parts of rats chronically treated with ethanol were analyzed
to estimate the level of 0-methylated metabolites of CAs. Substantial
increases of 3-methoxytyramine (130%) and nonnetanephrine (24%) were
-98-
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+
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HCHO,
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. ..
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•

HO

0.
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Fig. 21

~
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.
Q U1none
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Structural resemblance between a possible quinoid oxidation product
of a TIQ and the oxidized quinone of 6-hydroxy-DA (6-0H-DA)
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observed in the "alcoholic" rat brains compared to controls.

It is

known that DA is found in higher concentration in soluble fractions
(136) of nerve cells compared to particulate fractiomwhere NE is
stored (120).

Therefore DA would be more susceptible to the action

of CO!:'IT and would be expected to be more extensively 0-methylated
than is NE.
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APPENDIX I

AcD

acetaldehyde

CA

catecholamine

CNS

Central nervous system

COHT

catechol 0-methyltransferase

DA

dopamine

DHPG

3,4-dihydroxyphenylglycol

DOPA

3,4-dihydroxyphenylalanine

EC/GC

electron capture gas chromatography

E

epinephrine

GC

gas chromatogaphy

HFB-

heptafluorobutyric-

HCHO

formaldehyde

5-HIAA

5- hydroxyindole acetic acid

5-IIT

5- hydroxytriptamine

i.p.

intraperitoneal

i.v.

intravenous

LRT

long retention time

MAO

monoamine oxidase

MHPG

3-methoxy-4-hydroxyphenyl glycol

NAD

nicotinamide adenine dinucleotide

NADH

reduced nicotinamide adenine dinucleotide

NE

norepinephrine

PFP-

pentafluoropropionic-

TFA-

trifluoroacetic-

THP

tetrahydropapaveroline
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Appendix I (continued)

TIQ

1,2,3,4-tetrahydroisoquinoline

VMA

vanillylmandilic acid
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APPENDIX II
EFFECT OF ETHANOL ON ADRENAL GLAND PROTEIN AND CA CONCENTRATIONS

1

Drug
Treatment
Pyrogallol/
saline (6)

Weight of
adrenal
gland(mg)

Protein
%
Cone.
change
mg/gland prot.
from C

+
25.7 - 1.0

2.45 +
- 0.09

-

CA (ug/ g protein)

CA lug/ g ti.S.:'rne)

NE

DA

9.7;: 2.0

168

-.t

35

+

~·d,

NE

DA

E

434 ± 41

103 ! 21

1768

± 180

E
4557

± 330

(C)

*"'(
+
+
31. 2 - 1. 4"'( 2. 65 - 0 .12 tl.S 12.5 +
- 3.2
"/o';

Pyrogallol/
ethanol (6)

1

138 - 19

number of rats/group in parenthesis

*

p

**

p

<:::.::

<

0.01

compared to the pyrogallol/saline control

0.05

compared to the pyrogallol/saline control
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\
~

',

*

224 ~ 39

~·(

132

"±

22

+ **
1315 - 188

"k
+
2403 - 410
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